var docs;if (!docs) docs =[]; docs["33"]={"3300":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Ginkgo Biloba</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> The concomitant use of Ginkgo Biloba and Thiazide and Thiazide-Like Diuretics may result in hypertension. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patient blood pressure during concomitant use of ginkgo and thiazide diuretics. Though a decrease is expected, a paradoxical increase has been reported.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Case report. Paradoxical hypertension occurred in a patient receiving concomitant therapy with a thiazide diuretic and ginkgo biloba.<sup>1</sup> Ginkgo possesses known vasodilatory properties, and would thus suggest the potential for hypotension. Likewise, thiazides are expected to lower blood pressure. The mechanism of this reported interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shaw D, Leon C, Kolev S, et al, “Traditional Remedies and Food Supplements. A 5-Year Toxicological Study (1991-1995),” <i>Drug Saf</i>, 1997, 17(5):342-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9391777\">[PubMed 9391777]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3301":"<p><b>Title</b> Mycophenolate / Iron Salts</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Iron Salts may decrease the absorption of Mycophenolate. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action needed.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Carboxymaltose, Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In contrast to a previous study reporting a 91% decrease in mycophenolate acid (MPA; active metabolite of mycophenolate) AUC following coadministration of mycophenolate mofetil (MMF) (1000 mg single oral dose) with ferrous sulfate (two 525 mg sustained released tablets) in 7 healthy subjects,<sup>1</sup> several more recent studies have concluded that there is no significant interaction between mycophenolate and iron. In one study of 40 new renal transplant recipients, administration of MMF (1 g twice daily) either concomitantly with iron (two slow-release tablets daily) or 4 hours prior to iron resulted in no significant difference in MPA AUC compared to MMF administered without iron.<sup>2</sup> A study in 10 iron-deficient kidney transplant recipients similarly reported no significant change in MPA AUC following MMF (1 g) administration either together with or 4 hours prior to iron (ferrous sulfate, 105 mg elemental iron).<sup>3</sup> A study comparing MMF (1 g) alone or with iron (two 325mg doses of ferrous sulfate) in 16 healthy subjects also reported no significant change in MPA AUC with co-administered iron.<sup>4</sup> Further refuting the study reporting a negative impact of iron on mycophenolate concentrations, a study of 12 kidney transplant recipients reported that iron (polysaccharide iron complex) administered 2 hours after MMF significantly increased (by 21.9%) MPA 12-hour AUC, while concomitant administration of iron and MMF resulted in a small, non-significant increase (10.6%) in MPA 12-hour AUC.<sup>5</sup> Supporting these more recent studies, a study of the physico-chemical interaction between iron and MMF-MPA reported no evidence of a iron-MMF complex and other data suggesting a limited impact of iron on MMF or MPA.<sup>6</sup><br><br>The reason for the large interaction in one study that was not repeatable in subsequent studies is unclear. Potential explanations include the larger dose and sustained-release iron formulation used, simply a chance finding (ie, false positive or type I error), some other methodologic difference (concurrent medications, fasting vs. not, etc.), or a combination of these and other factors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. <i>Clin Pharmacol Ther</i>. 2000;68(6):613-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11180021\">[PubMed 11180021]</a></p>\n<p>2. Mudge DW, Atcheson B, Taylor PJ, et al. The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. <i>Transplantation</i>. 2004;77(2):206-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742982\">[PubMed 14742982]</a></p>\n<p>3. Lorenz M, Wolzt M, Weigel G, et al. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. <i>Am J Kidney Dis</i>. 2004;43(6):1098-1103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15168391\">[PubMed 15168391]</a></p>\n<p>4. Ducray PS, Banken L, Gerber M, Boutouyrie B, Zandt H. Absence of an interaction between iron and mycophenolate mofetil absorption. <i>Br J Clin Pharmacol</i>. 2006;62(4):492-495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16995871\">[PubMed 16995871]</a></p>\n<p>5. Gelone DK, Park JM, Lake KD. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. <i>Pharmacotherapy</i>. 2007;27(9):1272-1278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17723081\">[PubMed 17723081]</a></p>\n<p>6. Lidgate D, Brandl M, Holper M, Abubakari A, Wu X. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. <i>Drug Dev Ind Pharm</i>. 2002;28(10):1275-1283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12476873\">[PubMed 12476873]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3302":"<p><b>Title</b> Vitamin K Antagonists / Vitamin A</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vitamin A may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased INR/effects of coumarin derivatives if vitamin A is initiated/dose increased, or decreased INR/effects if vitamin A is discontinued/dose decreased. The only report to date cited use of 25,000 IU vitamin A daily.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The prothrombin activity (36 hours postdose) in 3 dicumarol-treated (150 mg single dose) normal subjects was decreased from 52% to 33% when administered following a 30-day course of vitamin E (42 IU/day).<sup>1</sup> The author states that “similar results” were obtained using vitamin A (25,000 IU/day) instead of vitamin E. The mechanism of this interaction is unknown. One author group has postulated that vitamin E may interfere with the vitamin K-dependent process of clotting factor production. Whether vitamin A might also affect the clotting system in this way is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schrogie JJ, “Letter: Coagulopathy and Fat-Soluble Vitamins,” <i>JAMA</i>, 1975, 232:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172961\">[PubMed 1172961]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3306":"<p><b>Title</b> Bisphosphonate Derivatives / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of bisphosphonate derivatives are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Bisphosphonate Derivatives. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exceptions</b> Magaldrate, Sodium Bicarbonate</p>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Risedronate, Tiludronate<br><b>Exceptions</b> Pamidronate, Zoledronic Acid</p>\n</div> \n<p><b>Discussion</b> The manufacturers of all oral bisphosphonate derivatives caution that absorption may be impaired by concomitant oral intake of antacids.<sup>1,2,3,4,5,6</sup> The likely primary mechanism of this interaction is binding of the bisphosphonate derivative to polyvalent cations to form a nonabsorbable (or very poorly absorbable) chelate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.</p>\n<p>2. Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>3. Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>4. Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.</p>\n<p>5. Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>6. Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3307":"<p><b>Title</b> Bisphosphonate Derivatives / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of bisphosphonate derivatives and iron salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Risedronate, Tiludronate<br><b>Exceptions</b> Pamidronate, Zoledronic Acid</p>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> The manufacturers of all oral bisphosphonate derivatives caution that absorption may be impaired by concomitant oral intake of polyvalent cations such as calcium and magnesium (most but not all specifically implicate iron).<sup>1,2,3,4,5,6</sup> The likely primary mechanism of this interaction is binding of the bisphosphonate derivative to iron ions to form a nonabsorbable (or very poorly absorbable) chelate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.</p>\n<p>2. Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>3. Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>4. Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.</p>\n<p>5. Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>6. Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3308":"<p><b>Title</b> Bisphosphonate Derivatives / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of bisphosphonate derivatives and magnesium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Risedronate, Tiludronate<br><b>Exceptions</b> Pamidronate, Zoledronic Acid</p>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> The manufacturers of all oral bisphosphonate derivatives caution that absorption may be impaired by concomitant oral intake of polyvalent cations such as magnesium.<sup>1,2,3,4,5,6</sup> The likely primary mechanism of this interaction is binding of the bisphosphonate derivative to magnesium ions to form a nonabsorbable (or very poorly absorbable) chelate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.</p>\n<p>2. Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>3. Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>4. Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.</p>\n<p>5. Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>6. Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3309":"<p><b>Title</b> Alpha1-Agonists / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for an increased or decreased effect of the alpha 1 agonist when combined with tricyclic antidepressants. Avoid use of the oxymetazoline/tetracaine nasal spray in patients treated with tricyclic antidepressants.</p>\n<div>\n <p><b>Alpha1-Agonists Interacting Members</b> Midodrine, Naphazoline (Nasal), Naphazoline (Ophthalmic), Oxymetazoline (Nasal), Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic)*, Phenylephrine (Topical), Propylhexedrine, Xylometazoline</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In one study (N=4), the blood pressure elevating effects of phenylephrine were studied before and after treatment with imipramine (25 mg three times daily for 5 days).<sup>1</sup> There was a 2 to 3 fold potentiation of the blood pressure elevating effect of phenylephrine after imipramine treatment. In contrast, two other studies report a decreased sensitivity to phenylephrine in the presence of amitriptyline.<sup>2,3</sup> <br><br>Although not alpha 1 selective agonists, the blood pressure elevating effects of epinephrine and norepinephrine (other sympathomimetic amines) were markedly increased (2- to 9-fold) in several reports when administered to patients receiving various tricyclic antidepressants (TCAs).<sup>1,2,4,5,6</sup> Sympathomimetic-related side effects (eg, headache, chest pain) were also reported in 3 patients receiving TCAs when concomitantly administered a local anesthetic combined with norepinephrine (1:25,000) for a dental procedure.<sup>7</sup><br><br>Prescribing information for imipramine and phenylephrine warns of the potential for the potentiation of pressor effects when these agents are combined.<sup>8,9</sup> The oxymetazoline/tetracaine nasal spray product labeling states that it should not be used in patients treated with TCAs.<sup>10</sup> The effect of TCAs on the hemodynamic effects of other alpha 1 agonists is unknown.<br><br>The proposed mechanism of this interaction is that tricyclic antidepressants block norepinephrine uptake into adrenergic neurons, thus leaving higher concentrations in the synapse. The exogenous administration of an alpha 1 agonist leads to overstimulation of the adrenergic receptors. Conflicting reports with phenylephrine but not with other sympathomimetic amines may reflect the ability of TCAs to also block peripheral alpha 1 receptors, thus opposing the action of the selective alpha 1 agonist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>2. Ghose K. Assessment of peripheral adrenergic activity and its interactions with drugs in man. <i>Eur J Clin Pharmacol</i>. 1980;17(4):233-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6105078\">[PubMed 6105078]</a></p>\n<p>3. Ghose K, Rama Rao VA, Bailey J, Coppen A. Antidepressant activity and pharmacological interactions of ciclazindol. <i>Psychopharmacology (Berl)</i>. 1978;57(1):109-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=96461\">[PubMed 96461]</a></p>\n<p>4. Svedmyr N. The influence of a tricyclic antidepressive agent (protriptyline) on some circulatory effects of noradrenaline and adrenaline in man. <i>Life Sci</i>. 1968;7(1):77-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5636628\">[PubMed 5636628]</a></p>\n<p>5. Mitchell JR, Cavanaugh JH, Arias L, Oates JA. Guanethidine and related agents. III. Antagonism by drugs which inhibit the norepinephrine pump in man. <i>J Clin Invest</i>. 1970;49(8):1596-1604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5431666\">[PubMed 5431666]</a></p>\n<p>6. Gershon S, Holmberg G, Mattsson E, Mattsson N, Marshall A. Imipramine hydrochloride. Its effects on clinical, autonomic and psychological functions. <i>Arch Gen Psychiatry</i>. 1962;6(1):96-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13898068\">[PubMed 13898068]</a></p>\n<p>7. Boakes AJ, Laurence DR, Lovel KW, O'Neil R, Verrill PJ. Adverse reactions to local anaesthetic-vasoconstrictor preparations. A study of the cardiovascular responses to Xylestin and Hostacain-with-Adrenaline. <i>Br Dent J</i> 1972;133(4):137-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4507157\">[PubMed 4507157]</a></p>\n<p>8. Imipramine [prescribing information]. Fairfield, NJ: Excellium Pharmaceutical Inc; October 2012.</p>\n<p>9. Phenylephrine hydrochloride. [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2012.</p>\n<p>10. Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3310":"<p><b>Title</b> Salicylates / Agents with Antiplatelet Properties</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Though combined therapy is at times used advantageously, an increased risk of bleeding is possible. Monitor for increased evidence of reduced platelet function (e.g., bleeding, bruising, etc.) during concomitant use of antiplatelet agents and salicylates.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel*, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine*, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid*, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Per the manufacturer of clopidogrel, aspirin coadministration does not appear to increase clopidogrel-induced changes in bleeding times.<sup>1</sup> It does note, however, that clopidogrel may enhance the risk of bleeding associated with gastrointestinal ulcers such as can be caused by aspirin therapy. Data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial demonstrated that the addition of clopidogrel to an aspirin-containing regimen in patients being treated for acute coronary syndromes has beneficial effects - reducing the risk of the composite outcome of death from cardiovascular causes, nonfatal MI, or stroke.<sup>2,3</sup> The risk of major bleeding, however, was increased. Ticlopidine may enhance aspirin-mediated effects on platelet aggregation.<sup>4</sup><br><br>According to anagrelide prescribing information, two clinical studies revealed greater inhibition of platelet aggregation (ex vivo) with the combination of single-dose anagrelide 1 mg and aspirin 900 mg or repeated daily doses of anagrelide 1 mg and aspirin 75 mg, both compared to aspirin alone.<sup>5</sup> Additionally, preliminary data from an observational study suggest that major hemorrhagic events are more common with anagrelide than with another unspecified cytoreductive treatment, and in most cases these events occur in patients receiving anti-aggregatory treatment (primarily aspirin). However, no increases in bleeding time, prothrombin time (PT), or activated partial thromboplastin time (aPTT) were observed with single-dose anagrelide 1 mg and aspirin 900 mg.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Plavix (clopidogrel). New York, NY: Bristol-Myers Squibb, 2000.</p>\n<p>2. CURE Trial Investigators, “Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes Without ST-Segment Elevation,” <i>N Engl J Med</i>, 2001, 345(7):494-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11519503\">[PubMed 11519503]</a></p>\n<p>3. CAPRIE Steering Committee, “A Randomised, Blinded Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE),” <i>Lancet</i>, 1996, 348:1329-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8918275\">[PubMed 8918275]</a></p>\n<p>4. Prescribing information. Ticlid (ticlopidine). Nutley, NJ: Roche Laboratories, 1999.</p>\n<p>5. Prescribing information. Agrylin (anagrelide). Wayne, PA: Shire US Inc., 11/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3312":"<p><b>Title</b> Theophylline Derivatives / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to the potential severity of theophylline toxicity, consider avoiding the concomitant use of theophylline and fluvoxamine. Other SSRIs would seem to be safe alternatives. Monitor for toxic effects of theophylline if fluvoxamine is initiated/dose increased, or decreased effects if fluvoxamine is discontinued/dose decreased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline was decreased by 70% in 12 normal subjects when administered following a 7-day course of fluvoxamine (50-100 mg/day).<sup>1</sup> Several case reports describe the development of theophylline-associated toxicities (eg, agitation, headache, tachycardia, vomiting) within as few as 2 days following the initiation of fluvoxamine therapy.<sup>2,3,4</sup> Maximum toxic effects appear to be noted after approximately 7 days of fluvoxamine initiation. Serum theophylline concentrations were often found to be increased two- to threefold. Another study identified no effect of a single dose of fluoxetine on the pharmacokinetics of a 30-minute infusion of aminophylline in 8 normal subjects.<sup>5</sup> Theophylline is metabolized via CYP1A2 and CYP3A4. Fluvoxamine inhibits both of the isoenzymes. Fluoxetine inhibits CYP3A4 and citalopram minimally inhibits CYP1A2. The other SSRIs inhibit neither of these isoenzymes to a clinically-significant extent. As such, fluvoxamine appears to be the only SSRI of concern.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rasmussen BB, Jeppesen U, Gaist D, et al, “Griseofulvin and Fluvoxamine Interactions With the Metabolism of Theophylline,” <i>Ther Drug Monit</i>, 1997, 19:56-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029748\">[PubMed 9029748]</a></p>\n<p>2. Diot P, Jonville AP, Gerard F, et al, “Possible Interaction Entre Theophylline et Fluvoxamine,” <i>Therapie</i>, 1991, 46:170-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1905066\">[PubMed 1905066]</a></p>\n<p>3. Sperber AD, “Toxic Interaction Between Fluvoxamine and Sustained Released Theophylline in an 11-Year-Old Boy,” <i>Drug Saf</i>, 1991, 6:P460-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1793525\">[PubMed 1793525]</a></p>\n<p>4. van den Brekel AM and Harrington L, “Toxic Effects of Theophylline Caused by Fluvoxamine,” <i>Can Med Assoc J</i>, 1994, 151:1289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7954177\">[PubMed 7954177]</a></p>\n<p>5. Mauro VF, Mauro LS, and Klions HA, “Effects of Single Dose Fluoxetine on Aminophylline Pharmacokinetics,” <i>Pharmacotherapy</i>, 1994, 14:367.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3313":"<p><b>Title</b> Amiodarone / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor increased effects and toxicities (eg, bradycardia, sinus arrest, decreased cardiac output) if amiodarone is combined with a nondihydropyridine calcium channel blocker (ie, diltiazem, verapamil).</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem, Verapamil</p>\n</div> \n<p><b>Discussion</b> A case report describes a 61-year-old female who was administered diltiazem (60 mg four times daily) for 4 days, and then started on amiodarone (600 mg twice daily).<sup>1</sup> After 4 days of concomitant therapy, she developed sinus arrest, low cardiac output, and oliguria. She required immediate discontinuation of both medications, ventricular pacing, and intravenous dopamine to stabilize her hemodynamics. Four days later she was started on amiodarone alone which she tolerated without incident.<sup>1</sup><br> <br>Amiodarone prescribing information states that nondihydropyridine calcium channel blockers could potentiate the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest, and atrioventricular (AV) block.<sup>2</sup> Close monitoring for these adverse events is recommended if these agents are combined.<sup>2</sup><br><br>The mechanism of this interaction is likely due to the additive effects of amiodarone and nondihydropyridine calcium channel blockers on both the sinoatrial and AV nodes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee TH, Friedman PL, Goldman L, Stone PH, Antman EM. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. <i>Am Heart J</i>. 1985;109(1):163-164. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3966317\">[PubMed 3966317]</a></p>\n<p>2. Cordarone (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; May, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3315":"<p><b>Title</b> Beta-Blockers / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling for pindolol states verapamil type calcium channel blockers must not be given IV to a patient being treated with a beta-blocker.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Though usually safe and effective during concomitant use, monitor for increased evidence of bradycardia, hypotension, or signs of heart failure during concomitant use of beta-blockers and nondihydropyridine calcium channel blockers. The Canadian labeling for pindolol states that verapamil-type calcium channel blockers must not be administered IV to a patient already being treated with a beta-blocker, and that if the combination must be used, close monitoring is required. Ophthalmic beta-blockers are likely of little concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol*, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nadolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem*, Verapamil*<br><b>Exception</b> Bepridil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In general, concomitant use of beta-blockers and calcium channel blockers is safe and advantageous in the treatment of cardiovascular conditions. However, their combined use does carry noted risk. The bradycardic and hypotensive effects of these agents may be additive in some patients.<sup>1,2,3,4,5</sup> Signs of heart failure have developed with concomitant nifedipine and a beta-blocker.<sup>6,7</sup> Even timolol eye drops can cause hemodynamic problems.<sup>8</sup> Additionally, some calcium channel blockers may cause increased serum concentrations of beta-blockers. Diltiazem has been shown to increase the serum concentrations of both propranolol (48%) and metoprolol (33%).<sup>9,10</sup> Verapamil has been reported to increase the serum concentrations of propranolol, metoprolol, and atenolol.<sup>10,11,12,13</sup> The action of diltiazem and verapamil is likely due to their ability to inhibit hepatic drug metabolizing enzymes, and thus reduce beta-blocker metabolism.Dihydropyridine calcium channel blockers have caused milder (sometimes none), clinically insignificant elevations in serum beta-blocker concentrations.<sup>14,15,16</sup> The mechanism by which this occurs is not known.<br><br>The Canadian labeling for pindolol states that verapamil-type calcium channel blockers must not be administered IV to a patient already being treated with a beta-blocker, and that if the combination must be used, close monitoring is required.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Packer M, Leon MB, Bonow RO, Kieval J, Rosing DR, Subramanian VB. Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. <i>Am J Cardiol</i>. 1982;50(4):903-912. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6751066\">[PubMed 6751066]</a></p>\n<p>2. Winniford MD, Markham RV Jr, Firth BG, Nicod P, Hillis LD. Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol. <i>Am J Cardiol</i>. 1982;50(4):704-710. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7124630\">[PubMed 7124630]</a></p>\n<p>3. McCourty JC, Silas JH, Tucker GT, Lennard MS. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. <i>Br J Clin Pharmacol</i>. 1988;25(3):349-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3358897\">[PubMed 3358897]</a></p>\n<p>4. Staffurth JS, Emery P. Adverse interaction between nifedipine and beta-blockade. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6259):225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6779963\">[PubMed 6779963]</a></p>\n<p>5. Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. <i>Br Med J</i>. 1980;281(6253):1462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7437840\">[PubMed 7437840]</a></p>\n<p>6. Anastassiades CJ. Nifedipine and beta-blocker drugs. <i>Br Med J</i>. 1980;281(6250):1251-1252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6107167\">[PubMed 6107167]</a></p>\n<p>7. Robson RH, Vishwanath MC. Nifedipine and beta-blockade as a cause of cardiac failure. <i>Br Med J (Clin Res Ed)</i>. 1982;284(6309):104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6797645\">[PubMed 6797645]</a></p>\n<p>8. Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. <i>Br Med J (Clin Res Ed)</i>. 1987;294(6565):155-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3109547\">[PubMed 3109547]</a></p>\n<p>9. Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. <i>Eur J Clin Pharmacol</i>. 1989;36(1):67-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2917591\">[PubMed 2917591]</a></p>\n<p>10. Hunt BA, Bottorff MB, Herring VL, Self TH, Lalonde RL. Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers. <i>Clin Pharmacol Ther</i>. 1990;47(5):584-591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2344707\">[PubMed 2344707]</a></p>\n<p>11. McLean AJ, Knight R, Harrison PM, Harper RW. Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol. <i>Am J Cardiol</i>. 1985;55(13 Pt 1):1628-1629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4003307\">[PubMed 4003307]</a></p>\n<p>12. Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris. <i>Am J Cardiol</i>. 1986;58(6):551-552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3529913\">[PubMed 3529913]</a></p>\n<p>13. Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ. Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man. <i>Eur J Clin Pharmacol</i>. 1988;35(4):363-366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3197744\">[PubMed 3197744]</a></p>\n<p>14. Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG. Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers. <i>Br J Clin Pharmacol</i>. 1990;29(5):497-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2350528\">[PubMed 2350528]</a></p>\n<p>15. Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S. Pharmacokinetic interactions between felodipine and metoprolol. <i>Eur J Clin Pharmacol</i>. 1987;31(5):575-578. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3830242\">[PubMed 3830242]</a></p>\n<p>16. Levine MA, Ogilvie RI, Leenen FH. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. <i>Clin Pharmacol Ther</i>. 1988;43(1):39-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2826066\">[PubMed 2826066]</a></p>\n<p>17. Visken (pindolol) [prescribing information]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3316":"<p><b>Title</b> BusPIRone / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of BusPIRone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of buspirone if diltiazem or verapamil is initiated/dose increased, or decreased effects if diltiazem or verapamil is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem*, Verapamil*<br><b>Exception</b> Bepridil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 9 healthy volunteers, coadministration of verapamil (80 mg orally three times daily) or diltiazem (60 mg orally three times daily) increased the AUC of buspirone (10 mg single oral dose) by 3.4 fold and 5.5 fold, respectively.<sup>1,2</sup> Subjective increases in buspirone effects were reported by some patients. <br><br>The likely primary mechanism of these interactions is verapamil or diltiazem inhibition of CYP3A4 mediated buspirone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. <i>Clin Pharmacol Ther</i>. 1998;63(6):640-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663178\">[PubMed 9663178]</a></p>\n<p>2. Buspar (buspirone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3317":"<p><b>Title</b> Cardiac Glycosides / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased concentrations/effects of cardiac glycosides if a nondihydropyridine calcium channel blocker (nonDHP CCB) is initiated/dose increased, or decreased concentrations/effects if a nonDHP CCB is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil*, DilTIAZem*, Verapamil*</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin*, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum digoxin concentrations (0.375 mg/day) increased by 34% in 12 healthy volunteers following 7 days of concomitant administration of bepridil (300 mg/day).<sup>1</sup> Heart rates were decreased in the subjects. Similar data for bepridil have been reported elsewhere.<sup>2</sup> <br><br>Use of diltiazem in combination with digitalis could result in additive effects on AV conduction prolongation.<sup>3</sup> Digitoxin and digoxin serum concentrations have increased 25% and 20%-50%, respectively, during coadministration with diltiazem.<sup>4,5</sup> The digoxin elimination half life also increased 21% during coadministration with diltiazem.<sup>6</sup> Similar data for diltiazem have been reported elsewhere. <sup>7,8,9</sup> <br><br>Serum concentrations of digitoxin and digoxin can increase 35% and 44%-75% respectively, in patients concomitantly receiving verapamil.<sup>7,10,11,12,13</sup> Greater increases are possible in patients with hepatic cirrhosis. In 19 healthy volunteers receiving digoxin (0.5mg/day) for four weeks, digoxin AUC increased 51%, steady state serum concentration increased 42%, and peak digoxin serum concentration increased 45% after two weeks of verapamil (160mg/day for 4 days and 240mg/day for 10 days).<sup>14</sup> The increase usually occurred in less than one week, and was more significant in patients receiving 240 mg/day of verapamil versus 160 mg/day.<sup>15</sup> Several similar cases involving both digitoxin and digoxin use with verapamil have reported toxicity (including asystole).<sup>4,16,17,18,19,20</sup> <br><br>Some non-dihydropyridine alternatives may also alter serum concentrations of cardiac glycosides. Nitrendipine may increase serum digoxin concentrations as much as 2 fold, but most data show little to no effect.<sup>15,21,22,23,24</sup> The following calcium channel blockers appear to have little to no effect on serum digoxin or digitoxin concentrations: amlodipine;<sup>25</sup> felodipine;<sup>26, 27</sup> isradipine;<sup>28</sup> nicardipine;<sup>5</sup> nimodipine;<sup>18</sup> and nisoldipine.<sup>21,29</sup> <br><br>The mechanism of these interactions is unknown. Renal secretion of digoxin, as measured by transcellular transport of digoxin in vitro, may be inhibited in the presence of verapamil.<sup>30</sup> Other data suggest verapamil decreases total body and non-renal digitoxin clearance, by 27% and 29% respectively, but does not decrease renal clearance of digoxin.<sup>7,11,31</sup> One study suggested that verapamil decreased biliary clearance by 43%, but not renal clearance.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Belz GG, Wistuba S and Matthews JH, “Digoxin and Bepridil: Pharmacokinetic and Pharmacodynamic Interactions,” <i>Clin Pharmacol Ther</i>, 1986, 39(1):65-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3484691\">[PubMed 3484691]</a></p>\n<p>2. Doose DR, Wallen S, Nayak RK, et al, “Pharmacokinetic Interaction of Bepridil and Digoxin at Steady-State,” <i>Clin Pharmacol Ther</i>, 1987, 41:204.</p>\n<p>3. Prescribing information. Cardizem (diltiazem hydrochloride). Bridgewater, NJ: BTA Pharmaceuticals Inc., November 2009. </p>\n<p>4. Belz GG, Doering W, Munkes R, et al, “Interaction Between Digoxin and Calcium Antagonists and Antiarrhythmic Drugs,” <i>Clin Pharmacol Ther</i>, 1983, 33(4):410-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6831819\">[PubMed 6831819]</a></p>\n<p>5. Lessem J and Bellinetto A, “Interaction Between Digoxin and the Calcium Antagonists Nicardipine and Tiapamil,” <i>Clin Therap</i>, 1983, 5(6):595-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6627286\">[PubMed 6627286]</a></p>\n<p>6. Rameis H, Magometschnigg D and Ganzinger U, “The Diltiazem-digoxin Interaction,” <i>Clin Pharmacol Ther</i>, 1984, 36(2):183-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6744777\">[PubMed 6744777]</a></p>\n<p>7. Maragno I, Santostasi G, Gaion R, et al, “Low- and Medium-dose Diltiazem in Chronic Atrial Fibrillation: Comparison with Digoxin and Correlation with Drug Plasma Levels,” <i>Am Heart J</i>, 1988, 116(2 Pt 1):385-92.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3400564\">[PubMed 3400564]</a></p>\n<p>8. Mahgoub AA, El-Medany AH and Abdulatif AS, “A Comparison Between the Effects of Diltiazem and Isosobide Dinitrate on Digoxin Pharmacodynamics and Kinetics in the Treatment of Patients With Chronic Ischemic Heart Failure,” <i>Saudi Med J</i>, 2002, 23(6):725-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12070557\">[PubMed 12070557]</a></p>\n<p>9. Kasmer RJ and Jones EM, “Diltiazem-Nifedipine-Digoxin Interaction,” <i>Drug Intell Clin Pharm</i>, 1986, 20(12):985-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816552\">[PubMed 3816552]</a></p>\n<p>10. Prescribing information. Calan (verapamil hydrochloride). New York, NY: Pfizer, July 2011. </p>\n<p>11. Hedman A, Angelin B, Arvidsson A, et al, “Digoxin-verapamil Interaction: Reduction of Biliary but not Renal Digoxin Clearance in Humans,” <i>Clin Pharmacol Ther</i>, 1991, 49(3): 256-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2007320\">[PubMed 2007320]</a></p>\n<p>12. Doering W, “Effect of Coadministration of Verapamil and Quinidine on Serum Digoxin Concentrations,” <i>Eur J Clin Pharmacol</i>, 1983, 25(4):517-521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6653647\">[PubMed 6653647]</a></p>\n<p>13. Maragno I, Gianotti C, Tropeano PF, et al, “Verapamil-Induced Changes in Digoxin Kinetics in Cirrhosis,” <i>Eur J Clin Pharmacol</i>, 1987, 32(3):309-311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3595704\">[PubMed 3595704]</a></p>\n<p>14. Rodin SM, Johnson BF, Wilson J, et al, “Comparative Effects of Verapamil and Isradipine on Steady-State Digoxin Kinetics,” <i>Clin Pharmacol Ther</i>, 1988, 43(6):668-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2967742\">[PubMed 2967742]</a></p>\n<p>15. Klein HO, Lang R, Weiss E, et al, “The Influence of Verapamil on Serum Digoxin Concentrations,” <i>Circulation</i>, 1982, 65:998-1003. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7074765\">[PubMed 7074765]</a></p>\n<p>16. Pedersen KE, Dorph-Pedersen A, Hvidt S, et al, “Digoxin-Verapamil Interaction,” <i>Clin Pharmacol Ther</i>, 1981, 30(3):311-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7273594\">[PubMed 7273594]</a></p>\n<p>17. Doering W, “Effect of Coadministration of Verapamil and Qunidine on Serum Digoxin Concentration,” <i>Eur J Clin Pharmacol</i>, 1983, 25(4):517-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6653647\">[PubMed 6653647]</a></p>\n<p>18. Kounis NG, “Asystole After Verapamil and Digoxin,” <i>Br J Clin Prac</i>, 1980, 34(2):57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6992826\">[PubMed 6992826]</a></p>\n<p>19. Kuhlmann J and Marcin S, “Effects of Verapamil on Pharmacokinetics and Pharmacodynamics of Digitoxin in Patients,” <i>Am Heart J</i>, 1985, 110(6):1245-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4072882\">[PubMed 4072882]</a></p>\n<p>20. Johannessen A, Rendtorff C and Poulsen S, “Digoxin Intoxication Induced by Verapamil in an Uremic Patient,” <i>Clin Nephrol</i>, 1985, 24(3):158-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4042447\">[PubMed 4042447]</a></p>\n<p>21. Ziegler R, Horstmann R, Wingender W, et al, “Do Dihydropyridines Influence Pharmacokinetic and Hemodynamic Parameters of Digoxin?” <i>J Clin Pharmacol</i>, 1987, 27:712.</p>\n<p>22. Kirch W, Hutt HJ, Heindemann H, et al, “Drug Interactions With Nitrendipine,” <i>J Cardiovasc Pharmacol</i>, 1984, 6:S982-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6085389\">[PubMed 6085389]</a></p>\n<p>23. Kirch W, Logemann C, Santos SR, et al, “Influence of Different Doses of Nitrendipine on Digoxin Plasma Concentrations,” <i>Br J Clin Pharmacol</i>, 1986, 23:111-2P.</p>\n<p>24. Kirch W, Longemann C, Santos SR, et al, “Nitrendipine Increases Digoxin Plasma Levels Dose Dependently,” <i>J Clin Pharmacol</i>, 1986, 26:553.</p>\n<p>25. Schwartz JB, “Amlodipine Does Not Affect Serum Digoxin Concentrations or Renal Clearance,” <i>Clin Res</i>, 1987, 35:380A.</p>\n<p>26. Kirch W, Laskowski M, Ohnhaus EE, et al, “Effects of Felodipine on Plasma Digoxin Levels and Haemodynamics in Patients With Heart Failure,” <i>J Intern Med</i>, 1989, 225(4):237-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2656902\">[PubMed 2656902]</a></p>\n<p>27. Dunnselman PH, Scaf AH, Kuntze CE, et al, “Digoxin-Felodipine Interaction in Patients With Congestive Heart Failure,” <i>Eur J Clin Pharmacol</i>, 1988, 35:461-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3069476\">[PubMed 3069476]</a></p>\n<p>28. Johnson BF, Wilson J, Marwaha R, et al, “The Comparative Effects of Verapamil and a New Dihydropyridine Calcium Channel Blocker on Digoxin Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1987, 42:66-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2954736\">[PubMed 2954736]</a></p>\n<p>29. Kirch W, Stenzel J, Dylewicz P, et al, “Influence of Nisoldipine on Haemodynamic Effects and Plasma Levels of Digoxin,” <i>Br J Clin Pharmacol</i>, 1986, 22(2):155-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3530303\">[PubMed 3530303]</a></p>\n<p>30. Nakamura T, Kakumoto M, Kazuhiko Y, et al, “Factors Influencing the Prediction of Steady State Concentrations of Digoxin,” <i>Biol Pharm Bull</i>, 2001, 24(4):403-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11305603\">[PubMed 11305603]</a></p>\n<p>31. Rodin SM, Johnson BF, Wilson J, et al, “Comparative Effects of Verapamil and Isradipine on Steady-State Digoxin Kinetics,” <i>Clin Pharmacol Ther</i>, 1988, 43(6):668-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2967742\">[PubMed 2967742]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3321":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for enhanced or prolonged effects of nondepolarizing neuromuscular blockers in patients receiving calcium channel blockers.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> In a published clinical study, the use of nicardipine reduced intraoperative vecuronium requirements by over 50%.<sup>1</sup> Additionally, two published case reports describe prolonged/difficult-to-reverse blockade by vecuronium or tubocurarine in patients receiving verapamil.<sup>2,3</sup> In contrast, patients who received nimodipine in one study experienced no changes in vecuronium onset and recovery times.<sup>4</sup> The mechanism of the potential interaction between nondepolarizing neuromuscular blocking agents (NMBs) and calcium channel blockers is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kawabata K, Sumikawa K, Kamibavashi T, et al, “Decrease in Vecuronium Infusion Dose Requirements by Nicardipine in Humans,” <i>Anesth Analg</i>, 1994, 79:1159-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7978442\">[PubMed 7978442]</a></p>\n<p>2. van Poorten JF, Dhasmana KM, Kuypers RS, et al, “Verapamil and Reversal of Vecuronium Neuromuscular Blockade,” <i>Anesth Analg</i>, 1984, 63:155-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6140886\">[PubMed 6140886]</a></p>\n<p>3. Jones RM, Cashman JN, Casson WR, et al, “Verapamil Potentiation of Neuromuscular Blockade. Failure of Reversal With Neostigmine but Prompt Reversal With Edrophonium,” <i>Anesth Analg</i>, 1985, 64:1021-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4041146\">[PubMed 4041146]</a></p>\n<p>4. Aysel I, Hepaguslar H, Balcioglu T, et al, “The Effects of Nimodipine on Vecuronium-Induced Neuromuscular Blockade,” <i>Eur J Anaesthesiol</i>, 2000, 17(6):383-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10928439\">[PubMed 10928439]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3322":"<p><b>Title</b> Calcium Channel Blockers (Dihydropyridine) / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased calcium channel blocker (CCB) effects (e.g., decreased blood pressure, increased heart rate, etc.) and/or altered (increased or decreased) quinidine effects if this combination is used.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Cilnidipine, Clevidipine, Efonidipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nitrendipine<br><b>Exceptions</b> Felodipine, Nisoldipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Available data suggest a possible two-way interaction between quinidine and dihydropyridine (DHP) calcium channel blockers (CCBs), where quinidine may increase concentration/effects of the DHP CCBs and the CCBs may increase or decrease quinidine concentrations.<br><br>The nifedipine AUC was an average of 37% higher when nifedipine (20 mg every 8 hours x 4 doses) and quinidine (200 mg every 8 hours x 4 doses) were coadministered in a study of 10 healthy volunteers.<sup>1</sup> Subjects also experienced a significant increase in heart rate (max increase averaged 18 bpm) that correlated with the increased in nifedipine concentrations. Another study reported an average 18% increase in nifedipine bioavailability and a non-significant decrease in nifedipine clearance when nifedipine (20 mg, single dose) was administered with quinidine (200 mg, single dose) in a study of 12 healthy volunteers.<sup>2</sup> An in vitro study similarly reported that quinidine inhibited the metabolism of nifedipine.<sup>3</sup> Quinidine prescribing information also cautions that quinidine may variably slow the metabolism of nifedipine (and other DHP CCBs) via what is presumed to be competitive inhibition of CYP3A4.<sup>4</sup><br><br>Data regarding the impact of the DHP CCBs on quinidine are, however, less consistent. One report describes an approximate 100% increase in quinidine concentrations after the discontinuation of nifedipine, an effect that the authors hypothesize is mediated by the hemodynamic effects of nifedipine rather than any type of enzyme induction.<sup>5</sup> Other reports have noted similar decreases in quinidine concentrations associated with concurrent nifedipine.<sup>6,7</sup> Conversely, a study in healthy volunteers reported an average 16% increase in quinidine bioavailability and a non-significant decrease in quinidine clearance with concurrent nifedipine,<sup>2</sup> and other studies have reported no quinidine pharmacokinetic changes with the combination of quinidine and either nifedipine or the DHP CCBs felodipine and nisoldipine.<sup>1,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bowles SK, Reeves RA, Cardozo L, et al, “Evaluation of the Pharmacokinetic and Pharmacodynamic Interaction Between Quinidine and Nifedipine,” <i>J Clin Pharmacol</i>, 1993, 33(8):727-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8408733\">[PubMed 8408733]</a></p>\n<p>2. Hippius M, Henschel L, Sigusch H, et al, “Pharmacokinetic Interactions of Nifedipine and Quinidine,” <i>Pharmazie</i>, 1995, 50(9):613-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7480098\">[PubMed 7480098]</a></p>\n<p>3. Koley AP, Robinson RC, Markowitz A, et al, “Drug-Drug Interactions: Effect of Quinidine on Nifedipine Binding to Human Cytochrome P450 3A4,” <i>Biochem Pharmacol</i>, 1997, 53(4):455-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9105395\">[PubMed 9105395]</a></p>\n<p>4. Prescribing information. Quinidine. Indianapolis, IN: Eli Lilly and Company, May 2002.</p>\n<p>5. Farringer JA, Green JA, O'Rourke RA, et al, “Nifedipine-Induced Alterations in Serum Quinidine Concentrations,” <i>Am Heart J</i>, 1984, 108:1570-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6507260\">[PubMed 6507260]</a></p>\n<p>6. Van Lith RM and Appleby DG, “Quinidine-Nifedipine Interaction,” <i>Drug Intell Clin Pharm</i>, 1985, 19:829-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4064916\">[PubMed 4064916]</a></p>\n<p>7. Green JA, Clementi WA, Porter C, et al, “Nifedipine-Quinidine Interaction,” <i>Clin Pharm</i>, 1983, 2:461-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6627876\">[PubMed 6627876]</a></p>\n<p>8. Bailey DG, Freeman DJ, Melendez LJ, et al, “Quinidine Interaction with Nifedipine and Felodipine: Pharmacokinetic and Pharmacodynamic Evaluation,” <i>Clin Pharmacol Ther</i>, 1993, 53:354-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453855\">[PubMed 8453855]</a></p>\n<p>9. Schall R, Muller FO, Groenewoud G, et al, “Investigation of a Possible Pharmacokinetic Interaction Between Nisoldipine and Quinidine in Healthy Volunteers,” <i>Drug Invest</i>, 1994, 8:162-70.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3327":"<p><b>Title</b> Opioid Analgesics / Octreotide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Octreotide may enhance the analgesic effect of Opioid Analgesics. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for possible decreased dose requirements if octreotide is added/dose increased or increased requirements if octreotide is discontinued/dose decreased.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone*, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Analgesia was reduced in a methadone-stable patient following the initiation of somatostatin therapy.<sup>1</sup> A 2.5-fold increase in methadone dosage did not fully compensate for this reduction. The same report describes three morphine-stable patients who likewise experienced analgesia reductions following the initiation of somatostatin. Morphine effects increased in the one patient of the latter report who discontinued somatostatin therapy. <br><br>In contrast to these cases, a randomized placebo-controlled study of 44 patients undergoing abdominal surgery showed decreased postoperative opioid requirements in patients who received intravenous octreotide infused at 0.33 mcg/kg/hr during surgery.<sup>2</sup> Additionally, a case series of 8 patients with intractable pain suggests analgesic efficacy and an opioid-sparing effect with intrathecal or epidural somatostatin administration (although these are not approved or well-investigated routes of administration).<sup>3</sup><br><br>The mechanism of interaction between these agents is unknown. Somataostatin and its analogs exert their physiologic effects at a group of receptors (SSTR1 - SSTR5, predominantly SSTR2) which are closely related to opioid receptors.<sup>4</sup> Additionally, the opioid and somatostatin recrptors have a number of overlapping second messengers and physiologic roles,<sup>5</sup> and under some circumstances morphine appears to bind SSRT2 receptors and displace somatostatin at these sites.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ripamonti C, De Conno F, Boffi R, et al, “Can Somatostatin Be Administered in Association With Morphine in Advanced Cancer Patients With Pain?” <i>Ann Oncol</i>, 1998, 9(8):921-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9789619\">[PubMed 9789619]</a></p>\n<p>2. Dahaba AA, Mueller GM, Mattiassich G, et al, “Effect of Somatostatin Analogue Octreotide on Pain Relief after Major Abdominal Surgery,” <i>Eur J Pain</i>, 2009, 13(8):861-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19084439\">[PubMed 19084439]</a></p>\n<p>3. Mollenholt P, Rawal N, Gordh T, et al, “Intrathecal and Epidural Somatostatin for Patients with Cancer. Analgesic Effects and Postmortem Neuropathologic Investigations of Spinal Cord and Nerve Roots,” <i>Anesthesiology</i>, 1994, 81(3):534-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7916546\">[PubMed 7916546]</a></p>\n<p>4. Viollet C, Prevost G, Maubert E, et al, “Molecular Pharmacology of Somatostatin Receptors,” 1995, 9(2):107-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628822\">[PubMed 7628822]</a></p>\n<p>5. Hatzoglou A, Kampa M and Castanas E, “Opioid-Somatostatin Interactions in Regulating Cancer Cell Growth,” <i>Front Biosci</i>, 2005, 10:244-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15574365\">[PubMed 15574365]</a></p>\n<p>6. Hatzglou A, Ouafik L, Bakogeorgou E, et al, “Morphine Cross-Reacts with Somatostatin Receptor SSTR2 in the T47D Human Breast Cancer Cell Line and Decreases Cell Growth,” <i>Cancer Res</i>, 1995, 55(23):5632-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7585646\">[PubMed 7585646]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3330":"<p><b>Title</b> Alfentanil / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Alfentanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> For patients who are receiving or have recently received fluconazole, caution should be used in administering alfentanil. Monitor for increased anesthetic and respiratory depressant effects, and consider using lower initial doses of alfentanil, or an alternative anesthetic.</p> \n<p><b>Discussion</b> In a randomized, cross-over, study, 9 healthy volunteers received intravenous (IV) alfentanil (20 mcg/kg over 2 minutes) during 3 separate phases of the study. One hour after alfentanil administration, the subjects received 400 mg of oral fluconazole (phase 1), 400 mg of IV fluconazole (phase 2), and placebo (phase 3). Each phase was separated by an interval of 4 weeks. Both oral and IV fluconazole increased the AUC of alfentanil by approximately 100%, increased the half-life of alfentanil by more than 65%, and decreased the clearance of alfentanil by approximately 60%.<sup>1</sup> <br><br>The mechanism for this interaction is likely fluconazole-mediated inhibition of CYP3A4 isoenzymes, a major metabolic pathway for alfentanil.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. <i>Anesth Analg</i>. 1998;87(1):190-194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9661572\">[PubMed 9661572]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3331":"<p><b>Title</b> Fluconazole / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Antacids do not appear to affect serum concentration of Fluconazole. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean fluconazole AUC and maximum serum concentration (Cmax) were not significantly different when fluconazole (100 mg capsule) was given immediately after a dose of an aluminum hydroxide- and magnesium hydroxide-containing antacid (20 mL; 1800 mg and 1200 mg, respectively) in a study of 14 healthy volunteers.<sup>1</sup> This lack of interaction is in contrast to ketoconazole and itraconazole, where administration of antacids and the presence of a less acidic gastric environment significantly impair absorption.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thorpe JE, Baker N, Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. <i>Antimicrob Agents Chemother</i>. 1990;34(10):2032-2033. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2291673\">[PubMed 2291673]</a></p>\n<p>2. Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. <i>J Antimicrob Chemother</i>. 1980;6(4):552-554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6253434\">[PubMed 6253434]</a></p>\n<p>3. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. <i>Antimicrob Agents Chemother</i>. 1982;21(1):151-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6282204\">[PubMed 6282204]</a></p>\n<p>4. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. <i>J Clin Pharm Ther</i>. 2005;30(3):201-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15896236\">[PubMed 15896236]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3332":"<p><b>Title</b> Vitamin K Antagonists / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider an empiric reduction in warfarin dose (of 10-20%) together with extra monitoring of warfarin response (i.e., INR testing, signs/symptoms of bleeding) to guide any further dose adjustment. One simulation study has suggested that larger dose reductions may be necessary, but that gradual warfarin dose reductions are superior to an immediate decrease to the predicted dose requirement. Increased monitoring for increased therapeutic/toxic effects of vitamin K antagonists is critical whenever using fluconazole in combination. Itraconazole, ketoconazole, and posaconazole might affect the anticoagulant less than fluconazole.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Combined use of fluconazole with warfarin was associated with approximately a 2-fold increased odds of hospitalization for gastrointestinal bleeding (compared to warfarin plus cephalexin) in a case-control study of Medicaid data for over 300,000 warfarin users.<sup>1</sup> The time period of greatest risk for hospitalization was 11-15 days after fluconazole initiation. A study in patients receiving low-intensity warfarin therapy who were given fluconazole (100mg daily x 7 days) reported an average 39% increase in prothrombin time (PT) by day 8.<sup>2</sup> Though no bleeding episodes were noted in the study, fluconazole therapy was stopped early in 3 patients due to excessively high PT values. The area under the prothrombin time curve (PT AUC) (as a measure of clinical warfarin effect), over 168 hours, was increased 10% to 100% in 13 normal subjects receiving a single dose of warfarin (15mg) following a 7-day course of fluconazole (200mg daily).<sup>3</sup> A similar study using pseudoracemic warfarin found a 44% increase in the PT AUC.<sup>4</sup> A study examining the impact of a single fluconazole dose on warfarin response found, on average, only a modest increase (34%) in prothrombin time (PT) at 5 days after a single dose of fluconazole (150mg) in a group of 6 women who had been on stable warfarin therapy for at least 6 months, but 3 of the 6 women did experience either an INR over 4 or a bleeding episode requiring a decrease in warfarin dose.<sup>5</sup> Numerous cases of bleeding due to this presumed interaction have also been reported.<sup>6,7,8,9</sup><br><br>Regarding optimal clinical management of this interaction, a series of simulation studies predicted that a gradual reduction in warfarin dose coincident with the start of fluconazole therapy would result in a more stable anticoagulant effect than a one-time reduction in warfarin dose.<sup>10</sup> Modeling the initiation of fluconazole 400mg daily, the simulation showed that administration of 80% of warfarin dose on day 1 of the combination, followed then by daily warfarin doses corresponding to 50%, 43%, and 36% of the pre-fluconazole dose, and then staying at 36% of the pre-fluconazole dose, was superior (at maintaining baseline S-warfarin concentrations) than a one-time reduction in warfarin dose to 36% of its pre-fluconazole levels.<sup>10</sup> Simulations for other fluconazole doses (50-400mg per day) predicted that warfarin dose reductions of 21-67% could be required for longer-term combination therapy.<br><br>Fluconazole (400mg daily x 6 days) has been shown to significantly inhibit the metabolism of warfarin (0.75mg/kg x1) in a clinical study of 6 healthy volunteers.<sup>11</sup> Following coadministration with fluconazole, formation of the main S- and R-warfarin metabolites were reduced by approximately 45-88%. Most significantly affected were the metabolism of S-warfarin by CYP2C9 and the 8-hydroxylation of R-warfarin via CYP2C19.<sup>11,12</sup> In support of these clinical observations, fluconazole has been shown in vitro to be a potent inhibitor of CYP2C9, the enzyme primarily responsible for metabolism of S-warfarin (the more active enantiomer), a potent inhibitor of CYP2C19, and a moderate inhibitor of CYP3A4.<sup>11,12,13,14,15</sup> Specific effects on acenocoumarol are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schelleman H, Bilker WB, Brensinger CM, et al, “Warfarin with Fluoroquinolones, Sulfonamides, or Azole Antifungals: Interactions and the Risk of Hospitalization for Gastrointestinal Bleeding,” <i>Clin Pharmacol Ther</i>, 2008, 84:581-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18685566\">[PubMed 18685566]</a></p>\n<p>2. Crussell-Porter LL, Rindone JP, Ford MA, et al, “Low-Dose Fluconazole Therapy Potentiates the Hypoprothrombinemic Response of Warfarin Sodium,” <i>Arch Intern Med</i>, 1993, 153:102-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8422191\">[PubMed 8422191]</a></p>\n<p>3. Lazar JD and Wilner KD, “Drug Interactions With Fluconazole,” <i>Ref Infect Dis</i>, 1990, 12 (Suppl 3):S327-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2330488\">[PubMed 2330488]</a></p>\n<p>4. Black DJ, Gidal BE, Seaton TL, et al, “An Evaluation of the Effect of Fluconazole on the Stereoselective Metabolism of Warfarin,” <i>Clin Pharmacol Ther</i>, 1992, 51:184.</p>\n<p>5. Turrentine MA, “Single-Dose Fluconazole for Vulvovaginal Candidiasis: Impact on Prothrombin Time in Women Taking Warfarin,” <i>Obstet Gynecol</i>, 2006, 107:310-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16449117\">[PubMed 16449117]</a></p>\n<p>6. Mootha VV, Schluter ML,Das A, “Intraocular Hemorrhages Due to Warfarin Fluconazole Drug Interaction in a Patient with Presumed Candida Endophthalmitis,” <i>Arch Ophthalmol</i>, 2002, 120:94-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11786068\">[PubMed 11786068]</a></p>\n<p>7. Seaton TL, Celum CL, and Black DJ, “Possible Potentiation of Warfarin by Fluconazole,” <i>DICP</i>, 1990, 24:1177-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2089826\">[PubMed 2089826]</a></p>\n<p>8. Baciewicz AM, Menke JJ, Bokar JA, et al, “Fluconazole-Warfarin Interaction,” <i>Ann Pharmacother</i>, 1994, 28:1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7803894\">[PubMed 7803894]</a></p>\n<p>9. Gericke KR, “Possible Interaction between Warfarin and Fluconazole,” <i>Pharmacotherapy</i>, 1993, 13:508-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8247921\">[PubMed 8247921]</a></p>\n<p>10. Kunze KL,Trager WF, “Warfarin-Fluconazole. III. A Rational Approach to Management of a Metabolically Based Drug Interaction,” <i>Drug Metab Dispos</i>, 1996, 24:429-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801058\">[PubMed 8801058]</a></p>\n<p>11. Black DJ, Kunze KL, Wienkers LC, et al, “Warfarin-Fluconazole. Ii. A Metabolically Based Drug Interaction: In Vivo Studies,” <i>Drug Metab Dispos</i>, 1996, 24:422-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801057\">[PubMed 8801057]</a></p>\n<p>12. Wienkers LC, Wurden CJ, Storch E, et al, “Formation of (R)-8-Hydroxywarfarin in Human Liver Microsomes. A New Metabolic Marker for the (S)-Mephenytoin Hydroxylase, P4502c19,” <i>Drug Metab Dispos</i>, 1996, 24:610-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8723744\">[PubMed 8723744]</a></p>\n<p>13. Lu C, Berg C, Prakash SR, et al, “Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole,” <i>Drug Metab Dispos</i>, 2008, 36:1261-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18381488\">[PubMed 18381488]</a></p>\n<p>14. Niwa T, Shiraga T, Takagi A, “Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes,” <i>Biol Pharm Bull</i>, 2005, 28:1805-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141567\">[PubMed 16141567]</a></p>\n<p>15. Kunze KL, Wienkers LC, Thummel KE, et al, “Warfarin-Fluconazole. I. Inhibition of the Human Cytochrome P450-Dependent Metabolism of Warfarin by Fluconazole: In Vitro Studies,” <i>Drug Metab Dispos</i>, 1996, 24:414-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801056\">[PubMed 8801056]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3335":"<p><b>Title</b> Sulfonylureas / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Seek alternatives to combined treatment with fluconazole and sulfonylureas when possible. If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or for decreased effects if fluconazole is discontinued/dose decreased.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride*, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, the combination of fluconazole (400 mg on day 1, 200 mg on days 2 through 4) and glimepiride (0.5 mg single dose on day 4) resulted in a 2.4-fold increase in AUC and a 1.5-fold increase in the maximum serum concentration (Cmax) of glimepiride.<sup>1</sup> In another pharmacokinetic study of 13 healthy participants, tolbutamide (500 mg single dose) given with fluconazole (150 mg single dose and 100 mg daily for 7 days) resulted in an increase in tolbutamide AUC by 90% to 108%.<sup>2</sup> No changes in blood glucose were observed in either pharmacokinetic study.<sup>1,2</sup><br><br>In a retrospective analysis of over 300,000 patients the odds ratio for an episode of severe hypoglycemia was greater for those exposed to fluconazole compared to those exposed to cephalexin for both glipizide treated (3.53 95% CI 2.19-5.69) and glyburide treated (2.00 95% CI 1.09-3.67) patients.<sup>3</sup> Another retrospective analysis of hospitalized patients reported that mean glucose values and maximum glycosylated hemoglobin values were significantly lower in patients who received a sulfonylurea (glimepiride, glibenclamide, or glipizide) and a CYP2C9 inhibitor (fluconazole was the CYP2C9 inhibitor in 11.4% of exposures) compared to patients who received a sulfonylurea alone (153 vs 164 mg/dL and 8.4 vs 9.2%, respectively).<sup>4</sup> <br><br>Severe hypoglycemia (blood glucose 40 mg/dL) was reported 7 days after a 56 year old HIV positive man stabilized on gliclazide was prescribed fluconazole 200 mg daily.<sup>5</sup> Of note, the patient was also prescribed sulfamethoxazole/trimethoprim (another 2C9 inhibitor) which may have also contributed to the perceived drug interaction. In contrast to the above data, no changes in glucose control were seen in 29 diabetic women (treated with either gliclazide or glibenclamide) randomized to receive either oral fluconazole (50 mg daily) or intravaginal clotrimazole for 14 days for the treatment of vulvovaginitis.<sup>6</sup><br><br>The likely mechanism for this potential interaction is fluconazole mediated inhibition of CYP2C9, an enzyme responsible for the metabolism of sulfonylureas.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen JP, Kivisto KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clin Pharmacol Ther</i>. 2001;69(4):194-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11309547\">[PubMed 11309547]</a></p>\n<p>2. Lazar JD, Wilner KD. Drug interactions with fluconazole. <i>Rev Infect Dis</i>. 1990;12(suppl 3):S327-S333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2330488\">[PubMed 2330488]</a></p>\n<p>3. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. <i>Clin Pharmacol Ther</i>. 2010;88(2):214-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20592722\">[PubMed 20592722]</a> </p>\n<p>4. Tirkkonen T, Heikkila P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. <i>J Intern Med</i>. 2010;268(4):359-366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20698928\">[PubMed 20698928]</a></p>\n<p>5. Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. <i>Br J Clin Pharmacol</i>. 2001;52(4):456-457. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11678792\">[PubMed 11678792]</a></p>\n<p>6. Rowe BR, Thorpe J, Barnett A. Safety of fluconazole in women taking oral hypoglycaemic agents. <i>Lancet</i>. 1992;339(8787):255-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1346224\">[PubMed 1346224]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3340":"<p><b>Title</b> Calcium Channel Blockers / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient closely for toxic effects of calcium channel blockers (CCB) if used together with a systemic azole antifungal. CCB dose reduction may be needed. Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated. Itraconazole may also possess negative inotropic properties, so particular caution is warranted if itraconazole is used together with verapamil or diltiazem due to the potential for additive or synergistic negative effects on cardiac contractility.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exceptions</b> Fluconazole, Isavuconazonium Sulfate</p>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of felodipine (single 5 mg dose) was increased more than 6-fold (and the Cmax nearly 8-fold), with increased felodipine effects, in 9 healthy subjects when administered following a 4-day course of itraconazole (200 mg/day).<sup>1</sup> The AUC of nisoldipine (5 mg single dose) increased 24-fold in 7 healthy subjects when administered following a 5-day course of ketoconazole (200 mg/day).<sup>5</sup> Blood pressure decreased in the subjects. Increased effects of calcium channel blockers (e.g., edema of the legs and ankles) following the addition of itraconazole have been reported elsewhere.<sup>2,3,4</sup> It is probable that the azole antifungals inhibit the CYP3A4 metabolism of the calcium channel blockers.<br><br>In addition, the itraconazole prescribing information cautions that itraconazole may exert negative effects on cardiac contractility, warranting special caution when used in patients with heart failure and/or if used together with other drugs that have negative effects on contractility (e.g., verapamil or diltiazem).<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jalava KM, Olkkola KT, and Neuvonen PJ, “Itraconazole Greatly Increases Plasma Concentrations and Effects of Felodipine,” <i>Clin Pharmacol Ther</i>, 1997, 61:410-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9129558\">[PubMed 9129558]</a></p>\n<p>2. Veuvonen PJ and Suhonen R, “Itraconazole Interacts With Felodipine,” <i>J Amer Acad Dermatol</i>, 1995, 33:134-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7601933\">[PubMed 7601933]</a></p>\n<p>3. Rosen T, “Debilitating Edema Associated With Itraconazole Therapy,” <i>Arch Dermatol</i>, 1994, 130:260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8304774\">[PubMed 8304774]</a></p>\n<p>4. Tailor SA, Gupta AK, Walker SE, et al, “Peripheral Edema Due to Nifedipine-Itraconazole Interaction: A Case Report,” <i>Arch Dermatol</i>, 1996, 132:350-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607648\">[PubMed 8607648]</a></p>\n<p>5. Heinig R, Adelmann HG, and Ahr G, “The Effect of Ketoconazole on the Pharmacokinetics, Pharmacodynamics, and Safety of Nisoldipine,” <i>Eur J Clin Pharmacol</i>, 1999, 55(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10206086\">[PubMed 10206086]</a></p>\n<p>6. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Centocor Ortho Biotech Products, L.P., November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3341":"<p><b>Title</b> Calcium Channel Blockers / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the calcium channel blocker (CCB) if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased. An adjustment in the dose of the CCB may be needed.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil<br><b>Exception</b> Clevidipine</p>\n</div> \n<p><b>Discussion</b> A case report describes a 16 year old patient with pheochromocytoma whose blood pressure was fairly well controlled on nifedipine while he was taking fluconazole, but he experienced increases in blood pressure (more than 10 mm Hg) upon repeated attempts to withdraw fluconazole therapy.<sup>1</sup> Pharmacokinetic analysis of this patient revealed that the maximum serum concentration and AUC of nifedipine increased 170% and 172%, respectively, in the presence of fluconazole.<sup>1</sup> <br><br>Other azole antifungal agents have also been shown to interact with various calcium channel blockers (CCB). The AUC of felodipine (single 5 mg dose) was increased more than 6-fold (and the Cmax nearly 8-fold), with increased felodipine effects, in 9 healthy subjects when administered following a 4-day course of itraconazole (200 mg/day).<sup>2</sup> The AUC of nisoldipine (5 mg single dose) increased 24-fold in 7 healthy subjects when administered following a 5-day course of ketoconazole (200 mg/day).<sup>3</sup> Increases in edema of the legs and ankles following the addition of itraconazole have been reported.<sup>4,5,6</sup><br><br>US product labeling warns that fluconazole has the potential to increase the systemic exposure of CCBs and that frequent monitoring for adverse events is recommended.<sup>7,8</sup><br><br>The probable mechanism of this interaction is fluconazole inhibition of the CYP3A4 metabolism of the CCB. The lesser magnitude of the interaction with fluconazole compared with other azole antifungal agents likely relates to the greater potency of CYP3A4 inhibition by ketoconazole and itraconazole compared with fluconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kremens B, Brendel E, Bald M, Czyborra P, Michel MC. Loss of blood pressure control on withdrawl of fluconazole during nifedipine therapy. <i>Br J Clin Pharmacol</i>. 1999;47(6):707-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10438200\">[PubMed 10438200]</a></p>\n<p>2. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. <i>Clin Pharmacol Ther</i>. 1997;61(4):410-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9129558\">[PubMed 9129558]</a></p>\n<p>3. Heinig R, Adelmann HG, Ahr G. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics, and safety of nisoldipine. <i>Eur J Clin Pharmacol</i>. 1999;55(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10206086\">[PubMed 10206086]</a></p>\n<p>4. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. <i>J Amer Acad Dermatol</i>. 1995;33(1):134-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7601933\">[PubMed 7601933]</a></p>\n<p>5. Rosen T. Debilitating edema associated with itraconazole therapy. <i>Arch Dermatol</i>. 1994;130(2):260-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8304774\">[PubMed 8304774]</a></p>\n<p>6. Tailor SA, Gupta AK, Walker SE, Shear NH. Peripheral edema due to nifedipine-itraconazole interaction: a case report. <i>Arch Dermatol</i>. 1996;132(3):350-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607648\">[PubMed 8607648]</a></p>\n<p>7. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p>8. <i>Adalat CC</i> (nifedipine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3343":"<p><b>Title</b> CarBAMazepine / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of carbamazepine if fluconazole is initiated/dose increased, or decreased serum concentrations/therapeutic effects of carbamazepine if fluconazole is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Four case reports describe patients whose serum carbamazepine concentration increased by 2-3 fold following fluconazole initiation or dose increase (150-400 mg/day, including one patient receiving intravenous fluconazole).<sup>1,2,3,4</sup> Three patients experienced symptoms associated with carbamazepine toxicity, including lethargy, diplopia, dizziness, nausea, vomiting, and gait instability.<sup>1,3,4</sup> Symptoms abated and carbamazepine concentrations returned to pre-fluconazole/dose increase levels within 24 hours of fluconazole discontinuation in all cases.<br><br>The mechanism of this interaction has not been investigated. Fluconazole could theoretically increase carbamazepine concentrations via inhibition of its metabolism (e.g., via CYP2C9, 3A4).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nair DR and Morris HH, “Potential Fluconazole-Carbamazepine Toxicity,” <i>Ann Pharmacother</i>, 1999, 33(7-8):790-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10466905\">[PubMed 10466905]</a></p>\n<p>2. Finch CK, Green CA and Self TH, “Fluconazole-Carbamazepine Interaction,” <i>South Med J</i>, 2002, 95(9):1099-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12356123\">[PubMed 12356123]</a></p>\n<p>3. Ulivelli M, Rubegni P, Nuti D, et al. “Clinical Evidence of Fluconazole-Induced Carbamazepine Toxicity,” <i>J Neurol</i>, 2004, 251(5):622-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15164201\">[PubMed 15164201]</a></p>\n<p>4. Tsouli S, Maranis S and Kyritsis AP, “Fluconazole-Carbamazepine Interaction in a Patient With Bipolar Disorder,” <i>Psychiatry Clin Neurosci</i>, 2011, 65(1):112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21265947\">[PubMed 21265947]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3344":"<p><b>Title</b> Cisapride / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of cisapride and systemic azole derivatives should be avoided. Neither miconazole nor clotrimazole are addressed in the cisapride package insert. US prescribing information specifically lists the use of fluconazole, itraconazole, ketoconazole, and voriconazole as contraindicated.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The manufacturer of cisapride states that fluconazole, itraconazole, and ketoconazole are contraindicated in patients receiving cisapride due to the potential for such concomitant therapy to cause serious cardiac arrhythmias (eg torsades de pointes).<sup>1</sup> Likewise, voriconazole prescribing information contraindicates the combination of voriconazole and cisapride.<sup>2</sup> These agents likely inhibit the CYP3A4 isoenzyme metabolism of cisapride, and thus increase cisapride serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Propulsid [package insert]. Titusville, NJ: Janssen Pharmaceutica; 1998.</p>\n<p>2. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc., March 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3349":"<p><b>Title</b> Antifungal Agents (Azole Derivatives, Systemic) / Didanosine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only expected with buffered didanosine preparations.</p></li>\n <li><p><b>Route</b> (oral): Only oral preparations of azole antifungal agents are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Didanosine may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> If concomitant therapy with didanosine buffered formulations and either ketoconazole or itraconazole oral capsules is needed administer the agents at least 2 hours apart in order to minimize the risk of interaction. Enteric-coated didanosine capsules should not interact with these azole antifungals, as this formulation does not contain buffering agents. Itraconazole oral solution will not likely be affected by buffered didanosine administration.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum itraconazole concentrations were decreased to undetectable values when coadministered with didanosine buffered formulation (300 mg).<sup>1</sup> A patient being treated with itraconazole for cryptococcal meningitis experienced a relapse when his anti-HIV therapy was changed from zidovudine to didanosine buffered formulation.<sup>2</sup> Limited effects on itraconazole concentrations were evident in 12 patients when didanosine was administered 2 or 4 hours later than the itraconazole.<sup>3</sup> When didanosine was administered 2 hours after doses of ketoconazole in 12 patients, no changes in ketoconazole pharmacokinetics were noted.<sup>4</sup> Fluconazole and didanosine, buffered formulation do not appear to interact.<sup>5</sup> Both itraconazole and ketoconazole require an acidic gastric environment in order to exist in an absorbable state. The buffer system in the nonenteric-coated didanosine formulations temporarily increases gastric pH to a level that inhibits absorption of these antifungals. Separating doses by at least 2 hours appears to minimize these effects. Nonbuffered formulations of didanosine do not appear to interact with ketoconazole.<sup>6</sup> Itraconazole oral solution, being already dissolved, may not be affected by buffered didanosine formulations.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. May DB, Drew RH, Yedinak KC, et al, “Effect of Simultaneous Didanosine Administration on Itraconazole Absorption in Healthy Volunteers,” <i>Pharmacotherapy</i>, 1994, 14:509-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7997384\">[PubMed 7997384]</a></p>\n<p>2. Moreno F, Hardin TC, Rinaldi MG, et al, “Itraconazole-Didanosine Excipient Interaction,” <i>JAMA</i>, 1993, 269:1508. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8383255\">[PubMed 8383255]</a></p>\n<p>3. Hardin TC, Sharkey-Mathis PK, Rinaldi MG, et al, “Evaluation of the Pharmacokinetic Interaction Between Itraconazole and Didanosine in HIV-Infected Subjects,” <i>Intersci Conf Antimicrob Ag Chemother</i>, 1995, 35:6.</p>\n<p>4. Knupp CA, Brater C, Relue J, et al, “Pharmacokinetics of Didanosine and Ketoconazole After Coadministration to Patients Seropositive for the Human Immunodeficiency Virus,” <i>J Clin Pharmacol</i>, 1993, 33:912-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8227460\">[PubMed 8227460]</a></p>\n<p>5. Bruzzese VL, Gillum JG, Israel DS, et al, “Effect of Fluconazole on Pharmacokinetics of 2’,3’-Dideoxyinosine in Persons Seropositive for Human Immunodeficiency Virus,” <i>Antimicrob Agents Chemother</i>, 1995, 9:1050-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7625787\">[PubMed 7625787]</a></p>\n<p>6. Damle BD, Mummaneni V, Kaul S, et al, “Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or Ciprofloxacin,” <i>Antimicrob Agents Chemother</i>, 2002, 46(2):385-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11796346\">[PubMed 11796346]</a></p>\n<p>7. Johnson MD, Hamilton CD, Drewr RH, et al, “A Randomized Comparative Study to Determine the Effects of Omeprazole on the Peak Serum Concentration of Itraconazole Oral Solution,” <i>J Antimicrob Chemother</i>, 2003, 51(2):453-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12562722\">[PubMed 12562722]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3351":"<p><b>Title</b> Losartan / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of losartan if a systemic azole derivative is initiated/dose increased, or decreased effects if a systemic azole derivative is discontinued/dose decreased.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The AUC of losartan (100 mg/day) was increased by 69% (and its active metabolite, E1374, decreased by 41%) in 16 normal subjects within 10 days of starting fluconazole (200 mg/day).<sup>1</sup> Three days of fluconazole (400 mg for 1 day and 200 mg for 2 days) increased the AUC of a single dose of losartan by 27%, and decreased the AUC of E1374 by 47%.<sup>2</sup> No significant changes in the blood pressure-lowering effects of losartan were identified. The pharmacokinetics of losartan (50 mg single dose) were essentially unchanged when administered following a 4-day course of itraconazole (200 mg/day).<sup>2</sup> Fluconazole inhibits CYP2C9, the major metabolic enzyme for losartan. Miconazole also inhibits CYP2C9. Neither itraconazole nor ketoconazole inhibit CYP2C9. However, like fluconazole and miconazole, they do inhibit CYP3A4, a secondary metabolic pathway for losartan. This is probably of less importance than the CYP2C9 effects, but caution may still be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kazierad DJ, Martin DE, Tenero D, et al, “Fluconazole Significantly Alters the Pharmacokinetics of Losartan But Not Eprosartan,” <i>Clin Pharmacol Ther</i>, 1997, 61:203. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9357393\">[PubMed 9357393]</a></p>\n<p>2. Kaukonen KM, Olkkola KT, and Neuvonen PJ, “Fluconazole But Not Itraconazole Decreases the Metabolism of Losartan to E-3174,” <i>Eur J Clin Pharmacol</i>, 1998, 53(6):445-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9551703\">[PubMed 9551703]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3352":"<p><b>Title</b> Losartan / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may decrease the serum concentration of Losartan. Specifically, fluconazole may decrease the serum concentration of E3174, the more potent active metabolite of losartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of losartan if fluconazole is initiated/dose increased, or increased effects if fluconazole is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study, 16 healthy volunteers received losartan 100 mg daily on days 1 through 20 and fluconazole 200 mg daily on days 11 through 20. Pharmacokinetic parameters on day 10 were compared with pharmacokinetic parameters on day 20.<sup>1</sup> The AUC of losartan was increased by 60%, while the AUC and maximum serum concentration (Cmax) of E3174, the active metabolite of losartan, decreased by 43% and 56%, respectively. In another study, four days of fluconazole (400 mg for 1 day and 200 mg for 3 days) followed by a single dose of losartan (50 mg) decreased the AUC of E3174 by 47% and the Cmax by 30%.<sup>2</sup> No significant changes in the blood pressure-lowering effects of losartan were identified. The pharmacokinetics of losartan and E3174 were essentially unchanged when administered following a 4-day course of itraconazole (200 mg/day).<sup>2</sup> <br><br>The likely mechanism for this interaction is fluconazole inhibition of CYP2C9 (an enzyme that itraconazole does not inhibit), the major metabolic enzyme responsible for conversion of losartan to its active metabolite E3174. E3174 is thought to be significantly more potent than losartan and is responsible for the majority of the angiotensin II receptor antagonism and therapeutic effect.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. <i>Clin Pharmacol Ther</i>. 1997;62(4):417-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9357393\">[PubMed 9357393]</a></p>\n<p>2. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. <i>Eur J Clin Pharmacol</i>. 1998;53(6):445-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9551703\">[PubMed 9551703]</a></p>\n<p>3. Munafo A, Christen Y, Nussberger J, et al. Drug concentration relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. <i>Clin Pharmacol Ther</i>. 1992;51(5):513-521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1587065\">[PubMed 1587065]</a></p>\n<p>4. <i>Cozaar</i> (losartan) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3354":"<p><b>Title</b> Antifungal Agents (Azole Derivatives, Systemic) / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs. Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely. Consider selecting alternative antifungal therapy. Voriconazole and fluconazole may also substantially increase phenytoin exposure; ketoconazole and itraconazole may have less of an effect on phenytoin pharmacokinetics. If voriconazole and phenytoin must be used together, adjust voriconazole dose as follows: patients &gt; 40 kg should receive 400 mg oral twice daily, and patients &lt;40 kg should receive 200 mg oral twice daily. IV maintenance doses should be 5 mg/kg every 12 hours. Also, serum phenytoin concentrations should be monitored, anticipating increased concentrations and the need to reduce the phenytoin dosage. If any azole antifungal is used concomitantly with phenytoin, monitor patients closely for azole therapeutic failure/relapse and phenytoin toxicity.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of itraconazole (single 200 mg dose) was reduced by &gt; 90% in 15 normal subjects when administered following a 15-day course of phenytoin (300 mg/day).<sup>1</sup> Six additional case reports describe therapeutic failure or relapse with itraconazole when concurrently receiving phenytoin alone or with phenobarbital.<sup>2,3</sup> Voriconazole (200 mg twice daily) AUC was reduced by approximately 70% with multiple concurrent doses of phenytoin (300 mg daily) in a study of 21 healthy subjects.<sup>4</sup> Coccidioidal meningitis relapse has been reported with ketoconazole following phenytoin initiation.<sup>5</sup> In contrast, fluconazole (a triazole antifungal) concentrations do not appear to be affected by phenytoin.<sup>6</sup> A probable mechanism for these interactions is phenytoin induction of CYP3A4 resulting in increased metabolism of itraconazole, voriconazole, and ketoconazole.<br><br>Both voriconazole and fluconazole also appear to alter phenytoin pharmacokinetics. Voriconazole (400 mg twice daily) increased the average phenytoin AUC by approximately 80% in a study of 15 healthy volunteers.<sup>4</sup> Similarly, fluconazole (200 mg daily) increased phenytoin AUC by an average of 75% more than placebo (n=20).<sup>6</sup> In another study, fluconazole (400 mg daily x 6 days) increased the phenytoin AUC by 33% following a single 250 mg phenytoin dose in 9 healthy volunteers.<sup>7</sup> Clinical phenytoin toxicity following initiation of higher doses of fluconazole have also been described.<sup>8</sup> Other azole antifungals appear to have less substantial effects on phenytoin pharmacokinetics. Single dose (300 mg) phenytoin AUC was an average of 10.3% higher after 15 days of itraconazole (200 mg daily) compared to baseline.<sup>1</sup> No other phenytoin pharmacokinetic parameters were significantly altered. Ketoconazole (200 mg twice daily x 6 days) also had no significant effects on phenytoin pharmacokinetics in a study of 9 healthy volunteers.<sup>7</sup> The suspected mechanism of this interaction is voriconazole and fluconazole inhibition of CYP2C9 and/or CYP2C19, both of which are important for phenytoin metabolism. Other azoles, such as itraconazole and ketoconazole, primarily inhibit CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ducharme MP, Slaughter RL, Warbasse LH, et al, “Itraconazole and Hydroxyitraconazole Serum Concentrations Are Reduced More Than Tenfold by Phenytoin,” <i>Clin Pharmacol Ther</i>, 1995, 58:617-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529326\">[PubMed 8529326]</a></p>\n<p>2. Tucker RM, Denning DW, Hanson LG, et al, “Interaction of Azoles With Rifampin, Phenytoin, and Carbamazepine: <i>In vitro</i> and Clinical Observations,” <i>Clin Infect Dis</i>, 1992, 14:165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1315160\">[PubMed 1315160]</a></p>\n<p>3. Hay RJ, Clayton YM, Moore MK, et al, “An Evaluation of Itraconazole in the Management of Onychomycosis,” <i>Br J Dermatol</i>, 1988, 119:359-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2846030\">[PubMed 2846030]</a></p>\n<p>4. Purkins L, Wood N, Ghahramani P, et al, “Coadministration of Voriconazole and Phenytoin: Pharmacokinetic Interaction, Safety, and Toleration,” <i>Br J Clin Pharmacol</i>, 2003, 56 Suppl 1:37-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616412\">[PubMed 14616412]</a></p>\n<p>5. Brass C, Galgiani JN, Blaschke TF, et al, “Disposition of Ketoconazole, an Oral Antifungal, in Humans,” <i>Antimicrob Agents Chemother</i>, 1982, 21:151-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6282204\">[PubMed 6282204]</a></p>\n<p>6. Blum RA, Wilton JH, Hilligoss DM, et al, “Effect of Fluconazole on the Disposition of Phenytoin,” <i>Clin Pharmacol Ther</i>, 1991, 49:420-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2015731\">[PubMed 2015731]</a></p>\n<p>7. Touchette MA, Chandrasekar PH, Milad MA, et al, “Contrasting Effects of Fluconazole and Ketoconazole on Phenytoin and Testosterone Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1992, 34:75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633070\">[PubMed 1633070]</a></p>\n<p>8. Cadle RM, Zenon GJ, 3rd, Rodriguez-Barradas MC, et al, “Fluconazole-Induced Symptomatic Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1994, 28:191-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8173131\">[PubMed 8173131]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3355":"<p><b>Title</b> Phenytoin / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of phenytoin if fluconazole is initiated or the dose is increased. Monitor for decreased therapeutic effects of phenytoin if fluconazole is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of phenytoin was increased by 75% in normal subjects within approximately 2 weeks of starting fluconazole (200 mg/day).<sup>1</sup> Similarly, phenytoin AUC was increased an average of 33% and the concentration at 48 hrs after a single phenytoin dose was increased an average of 132% when phenytoin (250 mg x1) was given on day 5 of fluconazole (400 mg/day x 6 days) in a study of 9 healthy volunteers.<sup>2</sup> Several cases of phenytoin toxicity associated with fluconazole therapy have also been reported.<sup>3,4,5</sup> In contrast, neither itraconazole nor ketoconazole appear to appreciably alter phenytoin pharmacokinetics.<sup>2,6</sup> A probable mechanism for the fluconazole-phenytoin interaction is inhibition of CYP2C9, resulting in decreased phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blum RA, Wilton JH, Hilligoss DM, et al, “Effect of Fluconazole on the Disposition of Phenytoin,” <i>Clin Pharmacol Ther</i>, 1991, 49:420-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2015731\">[PubMed 2015731]</a></p>\n<p>2. Touchette MA, Chandrasekar PH, Milad MA, et al, “Contrasting Effects of Fluconazole and Ketoconazole on Phenytoin and Testosterone Disposition in Man,” <i>Br J Clin Pharmacol</i>, 1992, 34(1):75-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633070\">[PubMed 1633070]</a></p>\n<p>3. Howitt KM and Oziemski MA, “Phenytoin Toxicity Induced by Fluconazole,” <i>Med J Aust</i>, 1989, 151:603-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2556633\">[PubMed 2556633]</a></p>\n<p>4. Mitchell AS and Holland JT, “Fluconazole and Phenytoin: A Predictable Interaction,” <i>Br Med J</i>, 1989, 298:1315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2544241\">[PubMed 2544241]</a></p>\n<p>5. Cadle RM, Zenon J III, Rodriguez-Barradas C, et al, “Fluconazole-Induced Symptomatic Phenytoin Toxicity,” <i>Ann Pharmacother</i>, 1994, 28:191-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8173131\">[PubMed 8173131]</a></p>\n<p>6. Ducharme MP, Slaughter RL, Warbasse LH, et al, “Itraconazole and Hydroxyitraconazole Serum Concentrations Are Reduced More Than Tenfold by Phenytoin,” <i>Clin Pharmacol Ther</i>, 1995, 58:617-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529326\">[PubMed 8529326]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3356":"<p><b>Title</b> QuiNIDine / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the use of quinidine in combination with any systemic azole antifungal agent. The manufacturers of all systemic azole antifungal agents list use with quinidine as contraindicated.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The manufacturers of itraconazole, ketoconazole, voriconazole, fluconazole, and posaconazole all specifically list their use in combination with quinidine as contraindicated.<sup>1,2,3,4,5</sup><br><br>The AUC of quinidine (100 mg single dose) increased 2.4-fold in 9 normal subjects when administered following a 4-day course of itraconazole (200 mg daily).<sup>6</sup> In another study of 6 healthy volunteers, quinidine (200mg oral once daily) clearance decreased 60% and the half-life increased 35% when administered with itraconazole (100 mg daily x 4 days).<sup>7</sup> A case report describes increased quinidine concentrations within a week of initiating ketoconazole therapy (200 mg/day).<sup>8</sup> The concentrations increased approximately 3-fold. The quinidine dosage was reduced, but then was returned to normal within approximately 1 month in order to maintain adequate serum concentrations.<sup>8</sup> <br><br>The mechanism of these interactions is likely related to the ability of the azole derivative to inhibit CYP3A4 isoenzymes, and thus reduce quinidine metabolism. The reason for the fluctuations in the case report involving ketoconazole is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sporanox</i> (itraconazole) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; March 2009.</p>\n<p>2. <i>Vfend</i> (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2008.</p>\n<p>3. <i>Noxafil</i> (posaconazole) [prescribing information]. Kenilworth, NJ: Schering Corporation; May 2008.</p>\n<p>4. <i>Nizoral</i> (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; February 2014.</p>\n<p>5. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p>6. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. <i>Clin Pharmacol Ther</i>. 1997;62(5):510-517. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390107\">[PubMed 9390107]</a></p>\n<p>7. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. <i>Br J Clin Pharmacol</i>. 1999;48(6):829-838. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594487\">[PubMed 10594487]</a></p>\n<p>8. McNulty RM, Lazor JA, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. <i>Clin Pharm</i>. 1989;8(3):222-225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706896\">[PubMed 2706896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3358":"<p><b>Title</b> Antifungal Agents (Azole Derivatives, Systemic) / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Due to the potential severity of outcomes from concomitant therapy with these agents (azole therapeutic failure/disease relapse; rifabutin-associated uveitis), such a combination should be avoided, if possible. If these agents are used concomitantly, monitor for evidence of reduced antifungal efficacy [in order of potency/risk: rifampin &gt; rifapentine &gt; rifabutin] or rifabutin toxicity (ie, uveitis). Refer to specific drug interaction monographs addressing voriconazole and isavuconazonium, which are considered contraindicated in combination with rifamycin derivatives per US prescribing information.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole*, Isavuconazonium Sulfate, Itraconazole*, Ketoconazole (Systemic), Posaconazole*, Voriconazole*</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum itraconazole and ketoconazole concentrations were reduced as much as 90% (often to undetectable values) in patients also receiving rifampin (plus isoniazid in some), and disease relapses have been reported.<sup>1,2,3,4,5,6</sup> Rifampin (600mg daily) reduced voriconazole maximum plasma concentration (Cmax) by 93% and AUC by 96% when administered together with voriconazole (200mg every 12 hours) in healthy subjects.<sup>7</sup> Rifabutin (300mg daily) had a similar effect when combined with voriconazole, reducing Cmax by 69% and AUC by 78%.<sup>7</sup> Fluconazole (200mg daily) AUC was decreased an average of 23% after 15 days of rifampin (600mg daily) in 8 healthy volunteers.<sup>8</sup> The mechanism of these interactions is likely CYP3A4 isoenzyme induction by rifampin leading to increased azole metabolism.<br><br>Posaconazole (200mg daily) average maximum plasma concentration was decreased 43%, and average AUC was decreased 49% by rifampin (300mg daily).<sup>9</sup> The mechanism of this interaction is suspected to be induction of UDP-glucuronosyltransferase enzymes, as posaconazole is metabolized by glucuronidation and not CYP3A4, unlike most other azole antifungals.<sup>9</sup> Of note, posaconazole is also transported by p-glycoprotein (like several other azoles), and rifamycin-mediated induction of p-glycoprotein transport may also be involved to some degree in this (and other azole-rifamycin) interaction.<br><br>Rifabutin serum concentrations have been significantly elevated when concurrently administered with azole antifungals,<sup>7,9,10</sup> and rifabutin toxicity (uveitis) has occurred when rifabutin was combined with an azole antifungal.<sup>8,11,12</sup> This is likely due to azole-mediated inhibition of CYP3A metabolism of rifabutin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Blomley M, Teare EL, De Belder A, et al, “Itraconazole and Antituberculosis Drugs,” <i>Lancet</i>, 1990, 2:1255. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1978097\">[PubMed 1978097]</a></p>\n<p>2. Tucker RM, Denning DW, Hanson LH, et al, “Interaction of Azoles With Rifampin, Phenytoin, and Carbamazepine: <i>In vitro</i> and Clinical Observations,” <i>Clin Infect Dis</i>, 1992, 14:165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1315160\">[PubMed 1315160]</a></p>\n<p>3. Drayton J, Dickinson G, and Rinaldi MG, “Coadministration of Rifampin and Itraconazole Leads to Undetectable Levels of Serum Itraconazole,” <i>Clin Infect Dis</i>, 1994, 18:266. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8161649\">[PubMed 8161649]</a></p>\n<p>4. Brass C, Galgiani JN, Blaschke TF, et al, “Disposition of Ketoconazole, an Oral Antifungal, in Humans,” <i>Antimicrob Agents Chemother</i>, 1982, 21:151-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6282204\">[PubMed 6282204]</a></p>\n<p>5. Drouhet E and DuPont B, “Laboratory and Clinical Assessment of Ketoconazole in Deep Seated Mycoses,” <i>Am J Med</i>, 1983, 74(1B):30-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6295150\">[PubMed 6295150]</a></p>\n<p>6. Abadie-Kemmerly S, Pankey GA, and Dalvisio JR, “Failure of Ketoconazole Treatment of <i>Blastomyces</i> Dermatitidis Due to Interaction of Isoniazid and Rifampin,” <i>Ann Intern Med</i>, 1988, 109(10):844-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3190036\">[PubMed 3190036]</a></p>\n<p>7. Prescribing information. Vfend (voriconazole). New York, NY: Pfizer Roerig, 2006.</p>\n<p>8. Prescribing information. Diflucan (fluconazole). New York, NY: Pfizer Inc., August 2004.</p>\n<p>9. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation, 10/06.</p>\n<p>10. Prescribing information. Sporanox (itraconazole). Titusville, NJ: Janssen Pharmaceutica Products, LP, June 2006.</p>\n<p>11. Becker K, Schimkat M, Jablonowski H, et al, “Anterior Uveitis Associated With Rifabutin Medication in AIDS Patients,” <i>Infection</i>, 1996, 24:34-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8852461\">[PubMed 8852461]</a></p>\n<p>12. Lefont A, Launay O, and Carbon C, “Uveitis Associated With Rifabutin Prophylaxis and Itraconazole Therapy,” <i>Ann Intern Med</i>, 1996, 125:939-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8967681\">[PubMed 8967681]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3367":"<p><b>Title</b> Cardiac Glycosides / Telmisartan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Telmisartan may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of cardiac glycosides if telmisartan is initiated/dose increased, or decreased serum concentrations/therapeutic effects if telmisartan is discontinued/dose decreased.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to U.S. prescribing information for telmisartan, coadministration of telmisartan with digoxin was associated with increases in the median peak (49%) and trough (20%) serum digoxin concentration.<sup>1</sup> Other available angiotensin II antagonists, in contrast, do not appear to affect, or be affected by, digoxin.<sup>2,3,4,5,6</sup> <br><br>The mechanism of the telmisartan interaction is not fully understood. Telmisartan inhibition of P-glycoprotein mediated digoxin transport could theoretically increase digoxin serum concentrations (e.g., via decreasing intestinal or renal digoxin efflux).<sup>7,8</sup> Digitoxin is also a P-glycoprotein substrate based on in vitro data,<sup>9</sup> but the impact of telmisartan on its pharmacokinetics has not been evaluated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Micardis (telmisartan). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 1998.</p>\n<p>2. Prescribing information. Avapro (irbesartan). Princeton, NJ: Bristol-Myers Squibb Co, 1999.</p>\n<p>3. Prescribing information. Diovan (valsartan). East Hanover, NJ: Novartis Pharmaceuticals, 2000.</p>\n<p>4. Jonkman JH, van Lier JJ, van Heiningen PN, et al, “Pharmacokinetic Drug Interaction Studies With Candesartan Cilexetil,” <i>J Hum Hypertens</i>, 1997, 11(Suppl 2):S31-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9331003\">[PubMed 9331003]</a></p>\n<p>5. Martin DE, Tompson D, Boike SC, et al, “Lack of Effect of Eprosartan on the Single Dose Pharmacokinetics of Orally Administered Digoxin in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 1997, 43:661-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9205830\">[PubMed 9205830]</a></p>\n<p>6. De Smet M, Schoors DF, De Meyer G, et al, “Effect of Multiple Doses of Losartan on the Pharmacokinetics of Single Doses of Digoxin in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 1995, 40:571-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8703664\">[PubMed 8703664]</a></p>\n<p>7. Weiss J, Sauer A, Divac N, et al, “Interaction of Angiotensin Receptor Type 1 Blockers With ATP-Binding Cassette Transporters,” <i>Biopharm Drug Dispos</i>, 2010, 31(2-3):150-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20222053\">[PubMed 20222053]</a></p>\n<p>8. Kamiyama E, Nakai D, Mikkaichi T, et al, “Interaction of Angiotensin II Type 1 Receptor Blockers With P-gp Substrates in Caco-2 Cells and hMDR1-Expressing Membranes,” <i>Life Sci</i>, 2010, 86(1-2):52-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19914261\">[PubMed 19914261]</a></p>\n<p>9. Pauli-Magnus C, Murdter T, Godel A, et al, “P-Glycoprotein-Mediated Transport of Digitoxin, Alpha-Methyldigoxin and Beta-Acetyldigoxin,” <i>Naunyn Schmiedebergs Arch Pharmacol</i>, 2001, 363(3):337-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11284449\">[PubMed 11284449]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3370":"<p><b>Title</b> Carmustine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may enhance the myelosuppressive effect of Carmustine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine in patients receiving carmustine. If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.</p> \n<p><b>Discussion</b> The incidence of leukopenia and thrombocytopenia were notably higher in one study where patients received carmustine (80 mg/m2) and steroids, with or without cimetidine (300 mg every 6 hours).<sup>1</sup> Patients receiving cimetidine experienced a 75% incidence of negative bone marrow-related effects while only 15% of those not receiving cimetidine experienced these same effects. Similar data have been published elsewhere.<sup>2</sup> <br><br>The mechanism of this interaction is unknown. Possible mechanisms include cimetidine inhibition of carmustine metabolism, leading to increased carmustine exposure,<sup>3</sup> and additive or synergistic bone marrow toxic effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Selker RG, Moore P, and LoDolce D, “Bone-Marrow Depression With Cimetidine Plus Carmustine,” <i>N Engl J Med</i>, 1978, 299:834. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=692572\">[PubMed 692572]</a></p>\n<p>2. Volkin RL, Shadduck RK, Winkelstein A, et al, “Potentiation of Carmustine-Cranial Irradiation-Induced Myelosuppression by Cimetidine,” <i>Arch Intern Med</i>, 1982, 142:243-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7059252\">[PubMed 7059252]</a></p>\n<p>3. Dorr RT and Soble MJ, “H2-Antagonists and Carmustine,” <i>J Cancer Res Clin Oncol</i>, 1989, 115(1):41-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2564000\">[PubMed 2564000]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3371":"<p><b>Title</b> Calcium Channel Blockers (Dihydropyridine) / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The nimodipine Canadian product monograph specifically states that this combination is contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may increase the metabolism of Calcium Channel Blockers (Dihydropyridine). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to dihydropyridine calcium channel blockers in patients receiving concomitant carbamazepine. If this combination is used, monitor for reduced therapeutic effects of the calcium channel blocker. Dose adjustment may be needed. The nimodipine Canadian product monograph specifically contraindicates concurrent use with carbamazepine.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Cilnidipine, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine*, Nisoldipine, Nitrendipine<br><b>Exception</b> Clevidipine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Compared to healthy subjects, felodipine AUC was approximately 93% lower in epileptic patients receiving carbamazepine, phenytoin, and/or phenobarbital after administration of felodipine (10 mg/day x 4 days followed by 5 mg on day 5) to both groups.<sup>1</sup> Similarly, nimodipine bioavailability and AUC were decreased by 80% or more in studies of individuals receiving concurrent anticonvulsant therapy (carbamazepine, phenobarbital, and/or phenytoin).<sup>2,3,4</sup> A single case report describes similar effects of carbamazepine coadministration on nilvadipine serum concentrations, along with apparent loss of antihypertensive effects.<sup>5</sup><br><br>The observed effects are likely due to the ability of the anticonvulsants to induce the CYP isoenzymes responsible for the metabolism of calcium channel blockers, particularly CYP3A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Capewell S, Freestone S, Critchley JA, et al, “Reduced Felodipine Bioavailability in Patients Taking Anticonvulsants,” <i>Lancet</i>, 1988, ii:480-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2900404\">[PubMed 2900404]</a></p>\n<p>2. Product Monograph. Nimotop (nimodipine). Toronto, Ontario: Bayer Inc., April 2009.</p>\n<p>3. Tartara A, Galimberti CA, Manni R, et al, “Differential Effects of Valproic Acid and Enzyme-inducing Anticonvulsants on Nimodipine Pharmacokinetics in Epileptic Patients,” <i>Br J Clin Pharmacol</i>, 1991, 32(3):335-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1777370\">[PubMed 1777370]</a></p>\n<p>4. Muck W, Ahr G and Kuhlmann J, “ Nimodipine. Potential for Drug-Drug Interactions in the Elderly.” <i> Drugs Aging</i>,1995, 6(3):229-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7620235\">[PubMed 7620235]</a></p>\n<p>5. Yasui-Furukori N and Tateishi T, “Carbamazepine Decreases Antihypertensive Effect of Nilvadipine.” <i> J Clin Pharmacol</i>, 2002, 42(1):100-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11808819\">[PubMed 11808819]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3372":"<p><b>Title</b> Calcium Channel Blockers (Nondihydropyridine) / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for toxic effects of carbamazepine if diltiazem or verapamil is initiated or the dose is increased. In addition, monitor for reduced therapeutic effects of the calcium channel blockers if carbamazepine is initiated or the dose is increased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem*, Verapamil*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Diltiazem has been shown to cause carbamazepine serum concentrations to increase by approximately 50% within 2-3 days of diltiazem initiation.<sup>1,2</sup> Much higher increases (e.g., 100% to 200%) have also been reported.<sup>3,4,5</sup> Likewise, verapamil (120 mg 3 times/day) has been shown to increase carbamazepine serum concentrations by 46% within 4 days.<sup>6</sup> Symptoms of carbamazepine toxicity (ataxia, diplopia, light-headedness) have been reported following initiation of either verapamil or diltiazem.<sup>1,2,6,7</sup> The likely primary mechanism of these interactions is calcium channel blocker inhibition of CYP3A4 mediated carbamazepine metabolism.<br><br>In addition to the above interactions, carbamazepine may decrease serum concentrations of non-dihydropyridine calcium channel blockers via induction of CYP3A4. Decreased calcium channel blocker effects are possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brodie MJ and Macphee GJ, “Carbamazepine Neurotoxicity Precipitated by Diltiazem,” <i>Br Med J</i>, 1986, 292:1170-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3085769\">[PubMed 3085769]</a></p>\n<p>2. Eimer M and Carter BL, “Elevated Serum Carbamazepine Concentrations Following Diltiazem Initiation,” <i>Drug Intell Clin Pharm</i>, 1987, 21:340-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3569036\">[PubMed 3569036]</a></p>\n<p>3. Ahmad S, “Diltiazem-Carbamazepine Interaction,” <i>Am Heart J</i>, 1990, 120: 1485. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2248204\">[PubMed 2248204]</a></p>\n<p>4. Bahls FH, Ozuna J, and Ritchie DE, “Interactions Between Calcium Channel Blockers and the Anticonvulsants Carbamazepine and Phenytoin,” <i>Neurology</i>, 1991, 41:740-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2027492\">[PubMed 2027492]</a></p>\n<p>5. Shaughnessy AF and Mosley MR, “Elevated Carbamazepine Levels Associated With Diltiazem Use,” <i>Neurology</i>, 1992, 42:937-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1565259\">[PubMed 1565259]</a></p>\n<p>6. Macphee GJ, McInnes GT, Thompson GG, et al, “Verapamil Potentiates Carbamazepine Neurotoxicity: A Clinically Important Inhibitory Interaction,” <i>Lancet</i>, 1986, i:700-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2870222\">[PubMed 2870222]</a></p>\n<p>7. Maoz E, Grossman E, Thaler M, et al, “Carbamazepine Neurotoxic Reaction After Administration of Diltiazem,” Arch Intern Med, 1992, 152(12):2503-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1456863\">[PubMed 1456863]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3373":"<p><b>Title</b> Procainamide / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Procainamide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider an alternative H2-receptor antagonist in patients taking procainamide. If combined, monitor for increased therapeutic effects/toxicity of procainamide.</p> \n<p><b>Discussion</b> Several studies have evaluated the effect of cimetidine on procainamide pharmacokinetics.<sup>1,2,3,4,5,6</sup> In 4 studies (N = 6 to 9), cimetidine (400 mg single dose or multiple daily doses) increased the procainamide AUC 35% to 43% and increased the N-acetylprocainamide (NAPA) AUC 25% to 45%.<sup>1,2,3,4,5</sup> Renal clearance of procainamide decreased 31% to 44%<sup>1,2,3,4,5</sup> and renal clearance of NAPA decreased 16% to 27% in 3 studies,<sup>1,2,4,5</sup> but remained unchanged in 1 study.<sup>3</sup> Mean steady-state serum concentrations of procainamide and NAPA increased 55% and 36%, respectively, in 36 procainamide-stable patients following 3 days of cimetidine therapy (300 mg every 6 hours).<sup>6</sup> One-third of the patients experienced procainamide-associated toxicity (eg, nausea, weakness, PR interval prolongation, and ventricular tachycardia).<sup>6</sup> Lastly, one case report supports these pharmacokinetic analyses and describes a 71-year-old male who developed procainamide toxicity along with elevated procainamide and NAPA serum concentrations after addition of cimetidine to his stable procainamide regimen.<sup>7</sup> <br><br>Other H2-receptor antagonists appear to have little effect on procainamide pharmacokinetics. Ranitidine increased procainamide serum concentrations by only 16% in one study,<sup>8</sup> and not at all in another.<sup>2</sup> Famotidine was also found to not affect the pharmacokinetics of procainamide.<sup>9</sup> <br><br>The mechanism of this interaction is likely inhibition of the renal tubular secretion of procainamide by cimetidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1988;26(3):118-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2457561\">[PubMed 2457561]</a></p>\n<p>2. Rodvold KA, Paloucek FP, Jung D, Gallastegui J. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine. <i>Ther Drug Monit</i>. 1987;9(4):378-383. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2447687\">[PubMed 2447687]</a></p>\n<p>3. Christian CD Jr, Meredith CG, Speeg KV Jr. Cimetidine inhibits renal procainamide clearance. <i>Clin Pharmacol Ther</i>. 1984;36(2):221-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6204803\">[PubMed 6204803]</a></p>\n<p>4. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. <i>Eur J Clin Pharmacol</i>. 1983;25(3):339-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6194997\">[PubMed 6194997]</a></p>\n<p>5. Somogyi A, Heinzow B. Cimetidine reduces procainamide elimination. <i>N Engl J Med</i>. 1982;307(17):1080. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6181402\">[PubMed 6181402]</a></p>\n<p>6. Bauer LA, Black D, Gensler A. Procainamide-cimetidine interaction in elderly male patients. <i>J Am Geriatr Soc</i>. 1990;38(4):467-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2329253\">[PubMed 2329253]</a></p>\n<p>7. Higbee MD, Wood JS, Mead RA. Procainamide-cimetidine interaction: a potential toxic interaction in the elderly. <i>J Am Geriatr Soc</i>. 1984;32(2):162-164. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6693705\">[PubMed 6693705]</a></p>\n<p>8. Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. <i>Br J Clin Pharmacol</i>. 1984;18(2):175-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6091709\">[PubMed 6091709]</a></p>\n<p>9. Klotz U, Arvela P, Rosenkranz B. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. <i>Eur J Clin Pharmacol</i>. 1985;28(6):671-675. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2866097\">[PubMed 2866097]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3374":"<p><b>Title</b> Sulfonylureas / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of sulfonylureas if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE*, GlyBURIDE*, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data describe the ability of cimetidine to increase the AUC of glipizide, glyburide, and tolbutamide, potentially resulting in decreased blood glucose concentrations.<sup>1,2,3,4</sup> This is possibly due to decreased hepatic metabolism and/or impaired renal transport of sulfonylureas caused by cimetidine. Not all data are confirming.<sup>5,6</sup> Ranitidine might also interact with sulfonylureas (eg, glyburide) to increase their hypoglycemic effects, but data is limited and contradictory.<sup>1,3,4,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cate EW, Rogers JF, and Powell JR, “Inhibition of Tolbutamide Elimination by Cimetidine But Not Ranitidine,” <i>J Clin Pharmacol</i>, 1986, 26:372-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3700691\">[PubMed 3700691]</a></p>\n<p>2. Feely J, Collins WC, Cullen M, et al, “Potentiation of the Hypoglycaemic Response to Glipizide in Diabetic Patients by Histamine H<sub>2</sub>-Receptor Antagonists,” <i>Br J Clin Pharmacol</i>, 1993, 35:321-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8471413\">[PubMed 8471413]</a></p>\n<p>3. Kubacka RT, Antal EJ, and Juhl RP, “The Paradoxical Effects of Cimetidine and Ranitidine on Glibenclamide Pharmacokinetics and Pharmacodynamics,” <i>Br J Clin Pharmacol</i>, 1987, 23:743-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3111514\">[PubMed 3111514]</a></p>\n<p>4. Toon S, Holt BL, Mullins FG, et al, “Effects of Cimetidine, Ranitidine, and Omeprazole on Tolbutamide Pharmacokinetics,” <i>J Pharm Pharmacol</i>, 1995, 47:85-8.</p>\n<p>5. Dey NG, Castleden CM, Ward J, et al, “The Effect of Cimetidine on Tolbutamide Kinetics,” <i>Br J Clin Pharmacol</i>, 1983, 16:438-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6626438\">[PubMed 6626438]</a></p>\n<p>6. Adebayo GI, Coker HA, “Lack of Efficacy of Cimetidine and Ranitidine as Inhibitors of Tolbutamide Metabolism,” <i>Eur J Clin Pharmacol</i>, 1988, 34(6):653-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3169118\">[PubMed 3169118]</a></p>\n<p>7. Lee K, Mize R, and Lowenstein SR, “Glyburide-induced Hypoglycaemia and Ranitidine,” <i>Ann Intern Med</i>, 1987, 107:261-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3111324\">[PubMed 3111324]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3375":"<p><b>Title</b> Pimozide / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of pimozide and any azole antifungal agent. Pimozide product labeling specifically contraindicates concomitant use with ketoconazole and itraconazole. Product labeling for other azole antifungals (eg voriconazole, posaconazole, fluconazole) list pimozide use as a contraindication.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> Although the combination of pimozide and azole antifungals has not been evaluated in a clinical study, the AUC of pimozide (6 mg single dose) was increased by more than 100%, and the maximum serum concentration increased by approximately 50%, in 12 healthy subjects following a 5-day course of the strong CYP3A4 inhibitor clarithromycin (500 mg twice daily).<sup>1</sup> The QTc<sub>max</sub> increased from 19 to 28 msec. Additionally, sudden deaths have been reported following the addition of clarithromycin to patients receiving pimozide.<sup>2,3</sup><br><br>Azole antifungal agents, like clarithromycin, have the ability to significantly inhibit CYP3A4 isoenzymes, and thus are specifically contraindicated for concomitant use with pimozide.<sup>3,4,5,6</sup> Inhibition of CYP3A4-mediated metabolism of pimozide (even with weak or moderate CYP3A4 inhibitors) may increase serum pimozide concentrations and lead to QTc interval prolongation and ventricular arrhythmias. Additionally, azole antifungals have been associated with increases in the QTc interval. Thus, in addition to the pharmacokinetic interaction between these agents, their combination may also result in additive QTc interval prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). <i>Clin Pharmacol Ther</i>. 1999;65(1):10-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951426\">[PubMed 9951426]</a></p>\n<p>2. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. <i>J Clin Psychopharmacol</i>. 2000;20(3):317-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10831018\">[PubMed 10831018]</a></p>\n<p>3. <i>Orap</i> (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011.</p>\n<p>4. <i>Vfend</i> (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; February 2014.</p>\n<p>5. <i>Noxafil</i> (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2012.</p>\n<p>6. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3376":"<p><b>Title</b> Pimozide / Nefazodone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nefazodone may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of pimozide lists concomitant use with nefazodone as contraindicated due to the risk of QTc interval prolongation and subsequent development of life-threatening arrhythmias.</p> \n<p><b>Discussion</b> Concurrent use of nefazodone with pimozide is specifically contraindicated according to pimozide prescribing information.<sup>1</sup> Nefazodone is considered a potent inhibitor of CYP3A4, which is one of the primary enzymes responsible for pimozide metabolism. As a result, use of this combination would be expected to result in decreased pimozide metabolism and increased serum pimozide concentrations, potentially leading to QTc interval prolongation and ventricular arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Orap (pimozide). Sellersville, PA: Teva Pharmaceuticals USA, 4/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3377":"<p><b>Title</b> Pimozide / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of pimozide and protease inhibitors. Product labeling for pimozide and all protease inhibitors list combined use as a contraindication.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Although the combination of pimozide and protease inhibitors has not been evaluated in a clinical study, the AUC of pimozide (6 mg single dose) was increased by more than 100%, and the maximum serum concentration increased by approximately 50%, in 12 healthy subjects when administered following a 5-day course of the strong CYP3A4 inhibitor clarithromycin (500 mg twice daily).<sup>1</sup> The QTc<sub>max</sub> increased from 19 to 28 msec. Additionally, sudden deaths have been reported following the addition of clarithromycin to patients receiving pimozide.<sup>2,3</sup><br><br>Protease inhibitors, like clarithromycin, have the ability to significantly inhibit CYP3A4 isoenzymes, and thus are specifically contraindicated for concomitant use with pimozide.<sup>3,4,5,6,7,8,9,10,11,12</sup> Inhibition of CYP3A4-mediated metabolism of pimozide may increase serum pimozide concentrations and lead to QTc interval prolongation and ventricular arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). <i>Clin Pharmacol Ther</i>. 1999;65(1):10-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951426\">[PubMed 9951426]</a></p>\n<p>2. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. <i>J Clin Psychopharmacol</i>. 2000;20(3):317-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10831018\">[PubMed 10831018]</a></p>\n<p>3. <i>Orap</i> (pimozide) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; August 2011.</p>\n<p>4. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014. </p>\n<p>5. <i>Prezista</i> (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; April 2014. </p>\n<p>6. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2013.</p>\n<p>7. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</p>\n<p>8. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013. </p>\n<p>9. <i>Viracept</i> (nelfinavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare Company; May 2013.</p>\n<p>10. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p>11. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; November 2012.</p>\n<p>12. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3378":"<p><b>Title</b> Ergot Derivatives / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Ergot Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of protease inhibitors and ergot derivatives is contraindicated. Even the use of single doses of an ergot derivative may be associated with serious toxicity in a patient who is being treated with a protease inhibitor.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine<br><b>Exceptions</b> Cabergoline, Nicergoline, Pergolide</p>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Many published reports describe cases of ergot toxicity (including ischemia of an extremity, coma, and even death) associated with concurrent use of an ergot alkaloid and a protease inhibitor.<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> The prescribing information for all protease inhibitors lists concurrent ergot derivatives as contraindicated.<sup>13,14,15,16,17,18,19,20,21,22</sup><br><br>As potent CYP3A4 inhibitors, protease inhibitors have the potential to significantly reduce the metabolism of ergot derivatives, and cause serious/life-threatening adverse events.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cagatay A, Guler O, Guven K, “Ergotism Caused by Concurrent Use of Ritonavir and Ergot Alkaloids: A Case Report,” <i>Acta Chir Belg</i>, 2009, 109(5):639-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19994812\">[PubMed 19994812]</a></p>\n<p>2. Pardo Rey C, Yebra M, Borrallo M, et al, “Irreversible Coma, Ergotamine, and Ritonavir,” <i>Clin Infect Dis</i>, 2003, 37(5):e72-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12942422\">[PubMed 12942422]</a></p>\n<p>3. Baldwin ZK, Ceraldi CC, “Ergotism Associated with HIV Antiviral Protease Inhibitor Therapy,” <i>J Vasc Surg</i>, 2003, 37(3):676-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12618710\">[PubMed 12618710]</a></p>\n<p>4. Tribble MA, Gregg CR, Margolis DM, et al, “Fatal Ergotism Induced by an HIV Protease Inhibitor,” <i>Headache</i>, 2002, 42(7):694-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12482227\">[PubMed 12482227]</a></p>\n<p>5. Vila A, Mykietiuk A, Bonvehi P, et al, “Clinical Ergotism Induced by Ritonavir,” <i>Scand J Infect Dis</i>, 2001, 33(10):788-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11728055\">[PubMed 11728055]</a></p>\n<p>6. Spiegel M, Schmidauer C, Kampfl A, et al, “Cerebral Ergotism Under Treatment with Ergotamine and Ritonavir,” <i>Neurology</i>, 2001, 57(4):743-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11524501\">[PubMed 11524501]</a></p>\n<p>7. Mortier E, Pouchot J, Vinceneux P, et al, “Ergotism Related to Interaction Between Nelfinavir and Ergotamine,” <i>Am J Med</i>, 2001, 110(7):594. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11347624\">[PubMed 11347624]</a></p>\n<p>8. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>9. Rosenthal E, Sala F, Chichmanian RM, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Indinavir,” <i>JAMA</i>, 1999, 281(11):987. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10086430\">[PubMed 10086430]</a></p>\n<p>10. Liaudet L, Buclin T, Jaccard C, et al, “Drug Points: Severe Ergotism Associated with Interaction Between Ritonavir and Ergotamine,” <i>BMJ</i>, 1999, 318(7186):771. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10082701\">[PubMed 10082701]</a></p>\n<p>11. Montero A, Giovannoni AG, Tvrde PL, “Leg Ischemia in a Patient Receiving Ritonavir and Ergotamine,” <i>Ann Intern Med</i>, 1999, 130(4 Pt 1):329-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10068398\">[PubMed 10068398]</a></p>\n<p>12. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>13. Prescribing information. Agenerase (amprenavir). Research Triangle Park, NC: GlaxoSmithKline, May 2005.</p>\n<p>14. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb, January 2010.</p>\n<p>15. Prescribing information. Prezista (darunavir). Raritan, NJ: Centocor Biotech Products, L.P., January 2010.</p>\n<p>16. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p>17. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., January 2010.</p>\n<p>18. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, January 2010.</p>\n<p>19. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., September 2008.</p>\n<p>20. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p>21. Prescribing information. Invirase (saquinavir). Nutley, NJ: Roche Laboratories Inc., January 2010.</p>\n<p>22. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3382":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Contraceptive failure is possible. If a protease inhibitor must be used in a patient desiring effective birth control, an estrogen-containing contraceptive (including non-oral formulations) may not provide adequate protection against conception. When atazanavir treated patients receive an oral contraceptive, provide at least 35 mcg/day ethinyl estradiol to patients receiving atazanavir/ritonavir, and no more than 30 mcg/day to patients receiving atazanavir without ritonavir. Patients receiving other protease inhibitors should use alternative, nonhormonal contraceptives. It is important to note that breakthrough bleeding, though an important sign regarding the diminished effect of hormonal contraceptives, might not be present in spite of the occurrence of an interaction.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir*, Darunavir*, Fosamprenavir*, Lopinavir*, Nelfinavir*, Ritonavir*, Saquinavir, Tipranavir<br><b>Exception</b> Indinavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of oral ethinyl estradiol has been reported to decrease by 37-55% when used in combination with ritonavir alone, and with ritonavir-boosted protease inhibitor regimens containing lopinavir, fosamprenavir, or darunavir.<sup>1,2,3,4</sup> In one of these studies, lopinavir/ritonavir also decreased transdermal ethinyl estradiol AUC by 45%.<sup>2</sup> The manufacturers of fosamprenavir, lopinavir, saquinavir, tipranavir, and darunavir all recommend the use of alternative or additional non-hormonal forms of contraception when the protease inhibitor is combined with low dose ritonavir.<sup>3,5,6,7,8</sup> <br><br>In clinical studies, atazanavir/ritonavir decreased ethinyl estradiol AUC by 19%, while atazanavir used alone increased ethinyl estradiol AUC by 48%.<sup>1,10</sup> Consequently, atazanavir prescribing information recommends use of a daily oral contraceptive containing at least 35 mcg ethyinyl estradiol with atazanavir/ritonavir, or use of an oral contraceptive containing no more than 30 mcg ethinyl estradiol with atazanavir alone (or use of alternative, nonhormonal contraception in either scenario).<sup>1</sup><br><br>Protease inhibitors without low dose ritonavir have variable effects on hormonal contraceptive estrogen exposure. The manufacturer of nelfinavir describes a 47% reduction is ethinyl estradiol AUC following 7 days of concomitant therapy, recommending additional or alternative forms of contraception be used.<sup>12</sup> In contrast, indinavir prescribing information describes a small, 22% increase in ethinyl estradiol AUC.<sup>12</sup><br><br>The mechanisms of these interactions have not been investigated. Ritonavir and some other protease inhibitors may induce enzymes mediating ethinyl estradiol metabolism (e.g., CYP3A4, 2C9). Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration. <br><br>In one of the above studies, the AUCs of lopinavir and ritonavir were reported to decrease by 19% and 24%, respectively, in women concomitantly receiving a contraceptive patch containing ethinyl estradiol and norelgestromin.<sup>2</sup> The mechanism and clinical impact of this effect are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ouellet D, Hsu A, Qian J, et al, “Effect of Ritonavir on the Pharmacokinetics of Ethinyl Oestradiol in Healthy Female Volunteers,” <i>Br J Clin Pharmacol</i>, 1998, 46(2):111-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9723818\">[PubMed 9723818]</a></p>\n<p>2. Vogler MA, Patterson K, Kamemoto L, et al, “Contraceptive Efficacy of Oral and Transdermal Hormones When Co-administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188,” <i>J Acquir Immune Defic Syndr.</i>, 2010, 55(4):473-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20842042\">[PubMed 20842042]</a></p>\n<p>3. Prescribing information. Lexiva (fosamprenavir calcium). Research Triangle Park, NC: GlaxoSmithKline, June 2009.</p>\n<p>4. Sekar VJ, Lefebvre E, Guzman SS, et al, “Pharmacokinetic Interaction Between Ethinyl Estradiol, Norethindrone and Darunavir With Low-Dose Ritonavir in Healthy Women,” <i>Antivir Ther</i>, 2008, 13(4):563-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18672535\">[PubMed 18672535]</a></p>\n<p>5. Prescribing information. Kaletra (lopinavir and ritonavir). North Chicago, IL: Abbott Laboratories, February 2011. </p>\n<p>6. Prescribing information. Fortovase (saquinavir). Nutley, NJ: Roche Laboratories Inc., April 2006.</p>\n<p>7. Prescribing information. Aptivus (tipranavir). Ridgefield CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2011. </p>\n<p>8. Prescribing information. Prezista (darunavir ethanolate). Raritan, NJ: Centocor Ortho Biotech Products, L.P., October 2010.</p>\n<p>9. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, March 2008.</p>\n<p>10. Zhang J, Chung E, Yones C, et al, “The Effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women,” <i>Antivir Ther</i>, 2011, 16(2):157-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21447864\">[PubMed 21447864]</a></p>\n<p>11. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc, February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3383":"<p><b>Title</b> Clarithromycin / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed. Clarithromycin may increase the serum concentration of Protease Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Avoid clarithromycin doses greater than 1000 mg/day in any patient who is also receiving a protease inhibitor. Saquinavir labeling lists concurrent use of clarithromycin as contraindicated. Patients with impaired renal function who are receiving concomitant clarithromycin and ritonavir and/or darunavir should have their clarithromycin dose adjusted as follows: Cl<sub>cr</sub> 30-60 mL/min, reduce clarithromycin dose by 50%; Cl<sub>cr</sub> &lt;30 mL/min, reduce clarithromycin dose by 75%. The manufacturer of atazanavir recommends that consideration be given to a 50% reduction in the dose of clarithromycin when coadministered with atazanavir. Also, consideration should be given to alternative antibiotic therapy for infections other than those due to <i>Mycobacterium avium</i>. For all patients receiving concomitant therapy with clarithromycin and a protease inhibitor, monitor for toxic effects of clarithromycin, including the potential for QT interval prolongation and the development of ventricular arrhythmias.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir*, Darunavir*, Fosamprenavir, Indinavir*, Lopinavir, Nelfinavir, Ritonavir*, Saquinavir, Tipranavir*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Protease inhibitors have been reported to increase the serum concentrations of clarithromycin to varying degrees. The AUC of clarithromycin (500 mg/day, days 7-10 and 18-21) was increased nearly 2-fold in 21 healthy volunteers when coadministered with atazanavir (400 mg/day, days 1-10).<sup>1</sup> The AUC of atazanavir was increased only 28%. Ritonavir (200 mg every 8 hours) increased the clarithromycin AUC by an average of 77% and nearly completely inhibited formation of the active 14-hydroxy-clarithromycin metabolite in a study of 22 healthy volunteers.<sup>2</sup> Darunavir/ritonavir (400 mg/100 mg twice daily x 7 days) increased clarithromycin AUC by an average of 57% in 17 healthy volunteers and decreased the AUC of 14-hydroxy-clarithromycin to below the limit of quantitation.<sup>3</sup> Similarly, combination tipranavir/ritonavir increased clarithromycin AUC by an average of 19% and decreased the 14-hydroxy-clarithromycin AUC by more than 90% in a study of 24 healthy volunteers.<sup>4</sup> With concurrent saquinavir (1200 mg three times/day) and clarithromycin (500 mg twice/day), the average clarithromycin AUC was 45% higher and the average 14-hydroxy-clarithromycin AUC was 24% lower in a study of 12 health volunteers.<sup>5</sup> These effects on the 14-hydroxy active metabolite is of potentially significant clinical importance as this metabolite is thought to account for a considerable portion of the total clarithromycin activity against <i>H. influenzae</i>.<sup>6,7</sup> In these studies, clarithromycin (500 mg twice daily) decreased darunavir AUC 13%, increased tipranavir AUC 66%, increased saquinavir AUC 2.8-fold, and increased ritonavir AUC by up to 12.5%.<sup>2,3,4,5</sup><br><br>The metabolism of clarithromycin (to its 14-hydroxy metabolite) is likely inhibited by the protease inhibitors via their effects on CYP3A4. Increased clarithromycin concentrations can increase the risk of drug-induced QT-prolongation and the development of life-threatening ventricular arrhythmias. Sauqinavir labeling contraindicates concurrent use with clarithromycin.<sup>8</sup> According to the U.S. clarithromycin prescribing information, doses greater than 1000 mg per day should not be administered to patients who are receiving protease inhibitors.<sup>5</sup> Also, decreased concentrations of the active 14-hydroxy-clarithromycin metabolite may negatively impact its effectiveness against certain organisms. Clarithromycin may alter protease inhibitor concentrations by inhibiting their metabolism via CYP3A. As one example of this, the average AUC of saquinavir was increased by 177% with concurrent clarithromycin (500 mg twice/day).<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2011.</p>\n<p>2. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. <i>Clin Pharmacol Ther</i>. 1998;64(4):355-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797791\">[PubMed 9797791]</a></p>\n<p>3. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. <i>J Clin Pharmacol</i>. 2008;48(1):60-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18094220\">[PubMed 18094220]</a></p>\n<p>4. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. <i>Pharmacotherapy</i>. 2007;27:888-909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17542771\">[PubMed 17542771]</a></p>\n<p>5. Biaxin (clarithromycin) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2011.</p>\n<p>6. Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. <i>Antimicrob Agents Chemother</i>. 1990;34:1407-1413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2143642\">[PubMed 2143642]</a></p>\n<p>7. Vallee E, Azoulay-Dupuis E, Swanson R, et al. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. <i>J Antimicrob Chemother</i>. 1991;27 Suppl A:31-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827100\">[PubMed 1827100]</a></p>\n<p>8. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genetech, Inc.; March 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3384":"<p><b>Title</b> Calcium Channel Blockers (Nondihydropyridine) / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider avoiding the concomitant use of protease inhibitors and nondihydropyridine calcium channel blockers (CCB). Use of saquinavir, tipranavir, and the darunavir/cobicistat combination product with bepridil is contraindicated. Monitor for evidence of toxic effects of the CCB if a protease inhibitor is initiated/dose increased. The manufacturer of atazanavir recommends that a 50% dose reduction for diltiazem be considered.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem*, Verapamil</p>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir*, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of diltiazem (180 mg/day, days 7-11 and 19-23) was increased more than twofold in 28 subjects when administered with atazanavir (400 mg/day, days 1-11).<sup>1</sup> No effect on atazanavir pharmacokinetics was noted. Atazanavir likely inhibited the CYP3A4 metabolism of diltiazem. Due to their inhibition of CYP3A4 isoenzymes, other protease inhibitors may reduce the metabolism of nondihydropyridine calcium channel blockers (CCB). Subsequent increases in serum CCB concentrations could result in augmentation of their effects on cardiac conduction, possibly leading to sinus arrest. Some CCB/protease inhibitor combinations are contraindicated by the manufacturer (eg, saquinavir, tipranavir, and darunavir/cobicistat with bepridil).<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir sulfate) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2010.</p>\n<p>2. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA Inc; February 2012.</p>\n<p>3. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; February 2012.</p>\n<p>4. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3385":"<p><b>Title</b> Propafenone / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Propafenone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of ritonavir and propafenone is contraindicated.</p> \n<p><b>Discussion</b> According to ritonavir prescribing information, concurrent use of ritonavir and propafenone is contraindicated.<sup>1</sup><br><br>The likely mechanism for this interaction is ritonavir-mediated inhibition of propafenone metabolism via CYP2D6 and CYP3A4.<sup>1,2</sup> Subsequent increases in serum propafenone concentrations could result in serious toxicity (e.g., cardiac arrhythmias).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, April 2010.</p>\n<p>2. Prescribing information. Rhythmol (propafenone). Research Triangle Park, NC: GlaxoSmithKline, October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3386":"<p><b>Title</b> Flecainide / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Flecainide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ritonavir and flecainide.</p> \n<p><b>Discussion</b> Prescribing information for ritonavir states that the concomitant use of ritonavir and flecanide is contraindicated.<sup>1</sup><br><br>The most likely mechanism of interaction between these drugs is ritonavir inhibition of CYP2D6-mediated metabolism of flecainide leading to an increase in flecainide concentration. This could result in an increase in flecanide toxicity including cardiac arrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, November 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3388":"<p><b>Title</b> Nefazodone / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Nefazodone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to, or reduced doses of, nefazodone in patients treated with HIV protease inhibitors. Monitor patients receiving nefazodone closely for toxicity following initiation or dose increase of an HIV protease inhibitor.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The ritonavir prescribing information cautions that concurrent use with nefazodone may result in increased nefazodone concentrations and that reductions in nefazodone dose may be needed.<sup>1</sup> Though not specifically mentioned in the prescribing information for other protease inhibitors, the fact that many of the protease inhibitors share ritonavir's ability to inhibit CYP3A and/or other drug metabolizing enzymes suggest that the risk for this potential interaction is likely shared by the other protease inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3389":"<p><b>Title</b> BuPROPion / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of bupropion if ritonavir is initiated/dose increased. Similarly, if ritonavir is discontinued, monitor for increased bupropion effects and toxicity. Avoid the use of naltrexone/bupropion for weight management in patients receiving ritonavir.</p> \n<p><b>Discussion</b> Ritonavir (400 mg twice daily) significantly decreased the bupropion AUC after both 3 days and 2.5 weeks (16% and 33% decrease versus control, respectively) of concurrent therapy in 13 healthy volunteers.<sup>1</sup> The ratio of hydroxybupropion (active metabolite)/bupropion was significantly increased, and the formation clearance of the hydroxybupropion metabolite was increased more than 2-fold after 2.5 weeks of ritonavir. In clinical studies summarized in naltrexone/bupropion US prescribing information, coadministration of ritonavir 100 mg daily for 17 days decreased the maximum concentration (Cmax) and AUC of bupropion by 21% and 22%, respectively, decreased the AUC of hydroxybupropion by 23%, and also decreased exposure to 2 other metabolites (threohydrobupropion and erythrohydrobupropion).<sup>2</sup> Coadministration of ritonavir 600 mg twice daily for 8 days decreased the Cmax and AUC of bupropion (62% and 66%, respectively), hydroxyupropion (42% and 78%, respectively), and the other metabolites to a greater extent.<sup>2</sup><br><br>Two weeks of combined lopinavir/ritonavir (400mg/100mg twice daily) decreased bupropion (single 100mg dose) AUC by 57% in a study of 12 healthy volunteers.<sup>3</sup> Hydroxybupropion AUC was also an average of 50% lower with ritonavir in this study. Conversely, a study of shorter-term ritonavir (200mg twice daily x 2 days) reported only minimal changes (less than 20%) of ritonavir on bupropion (and hydroxybupropion) in 7 healthy volunteers.<sup>4</sup><br><br>The suspected mechanism of this interaction is induction of bupropion metabolism via ritonavir-mediated CYP2B6 induction.<sup>1,3</sup> This is in contrast to in vitro data that had suggested ritonavir was an inhibitor of CYP2B6.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. <i>Antimicrob Agents Chemother</i>. 2008;52(5):1663-1669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18285471\">[PubMed 18285471]</a></p>\n<p>2. <i>Contrave</i> (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p>3. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM.Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. <i>Clin Pharmacol Ther</i>. 2007;81(1):69-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17186001\">[PubMed 17186001]</a></p>\n<p>4. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. <i>J Clin Pharmacol</i>. 2006;46(5):567-576. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16638740\">[PubMed 16638740]</a></p>\n<p>5. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. <i>Drug Metab Dispos</i>. 2001;29(2):100-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11159797\">[PubMed 11159797]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3390":"<p><b>Title</b> Vitamin K Antagonists / Dicloxacillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dicloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of vitamin K antagonists (eg, decreased INR, therapeutic failure) if dicloxacillin is initiated/dose increased, or increased effects if dicloxacillin is discontinued/dose decreased. Effects may last for several days (even weeks) following dicloxacillin discontinuation.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A retrospective database analysis of 236 vitamin K antagonist-treated patients in Denmark found that average INR values dropped significantly 2 to 4 weeks after initiation of dicloxacillin (2.59 vs 1.97; <i>P</i> less than 0.001).<sup>1</sup> The majority of patients (61%) experienced subtherapeutic INR vales (INR less than 2.0) 2 to 4 weeks after starting dicloxacillin. As a control, INR values were also compared before and after initiation of amoxicillin. Amoxicillin use was associated with a small increase in INR (2.58 vs 2.72; <i>P</i> = 0.03).<sup>1</sup> In another study, the mean prothrombin time (PT) was decreased approximately 2 seconds in 7 warfarin-treated patients following 7 days of concurrent therapy with dicloxacillin.<sup>2</sup> One retrospective review of 7 patients who received both warfarin and dicloxacillin found that patients experienced an average 17% decrease in PT compared to baseline.<sup>3</sup> Several case reports also describe decreases in INR and increased warfarin requirements in patients treated with dicloxacillin.<sup>3,4,5</sup> In many cases, the effects of dicloxacillin lasted for up to 2 weeks following discontinuation and substantial increases in the dose of warfarin (approximately 70%) were required to maintain a therapeutic INR.<sup>3,4,5</sup> In one case, serum levels of R- and S-warfarin were measured and dicloxacillin use resulted in a 20% and 25% decrease, respectively.<sup>3</sup><br><br>The mechanism of this interaction has not been fully investigated, but induction of CYP3A4 by dicloxacillin, an enzyme responsible for R-warfarin metabolism, may contribute.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pottegard A, Henriksen DP, Madsen KG, Hellfritzsch M, Damkier P, Stage TB. Change in international normalized ratio among patients treated with dicloxacillin and vitamin K antagonists. <i>JAMA</i>. 2015;314(3):296-297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26197191\">[PubMed 26197191]</a></p>\n<p>2. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. <i>Clin Pharm</i>. 1987;6(10):804-806. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3505843\">[PubMed 3505843]</a></p>\n<p>3. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. <i>Ann Pharmacother</i>. 1996;30(12):1402-1407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8968452\">[PubMed 8968452]</a></p>\n<p>4. Taylor AT, Pritchard DC, Goldstein AO, Fletcher JL Jr. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. <i>J Fam Pract</i>. 1994;39(2):182-185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8057070\">[PubMed 8057070]</a></p>\n<p>5. Lacey CS. Interaction of dicloxacillin with warfarin. <i>Ann Pharmacother</i>. 2004;38(5):898. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15054148\">[PubMed 15054148]</a></p>\n<p>6. Yasuda K, Ranade A, Venkataramanan R, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate the pregnane X receptor and induce CYP3A4 in liver and intestine. <i>Drug Metab Dispos</i>. 2008;36(8):1689-1697. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18505790\">[PubMed 18505790]</a></p>\n<p>7. Coumadin (warfarin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co; October, 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3397":"<p><b>Title</b> Corticosteroids (Systemic) / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic or toxic effects of systemic corticosteroids if an estrogen derivative is initiated/dose increased, or decreased effects if an estrogen derivative is discontinued/dose decreased. These effects are probably of little consequence in patients receiving nonsystemic corticosteroid therapy (e.g., inhalation, topical).</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone*, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of a single dose of prednisolone was increased by approximately 6-fold in six women taking estrogen-containing oral contraceptives (clearance was decreased).<sup>1</sup> Similar results were reported in a study comparing the clearance and AUC of prednisolone in both male (n=8) and female (n=13) subjects. Eight of the female subjects were receiving oral contraceptives. The oral contraceptive group demonstrated an approximate 50% reduction in steroid clearance and a 100% increase in steroid AUC.<sup>2</sup> Similarly, other reports describe similar findings in patients receiving prednisolone or methylprednisolone.<sup>3,4,5,6,7</sup> The effectiveness and toxicity of the steroids have been noted to increase. The mechanism of these interactions is not firmly established, but may be related to an estrogen-induced change in: 1) steroid metabolism; or 2) the ability of the steroid to bind to serum proteins. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Legler UF and Benet LZ, “Marked Alterations in Prednisolone Elimination for Women Taking Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1982, 31:243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3956058\">[PubMed 3956058]</a></p>\n<p>2. Boekenoogen SJ, Szefler SJ, and Jusko WJ, “Prednisolone Disposition and Protein Binding in Oral Contraceptive Users,” <i>J Clin Endocrinol Metab</i>, 1983, 56:702-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6833459\">[PubMed 6833459]</a></p>\n<p>3. Legler UF and Benet LZ, “Marked Alterations in Dose-Dependent Prednisolone Kinetics in Women Taking Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1986, 39:425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3956058\">[PubMed 3956058]</a></p>\n<p>4. Frey BM, Schaad HJ, and Frey FJ, “Pharmacokinetic Interaction of Contraceptive Steroids With Prednisone and Prednisolone,” <i>Eur J Clin Pharmacol</i>, 1984, 26:505-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734709\">[PubMed 6734709]</a></p>\n<p>5. Meffin PJ, Wing LM, Sallustio BC, et al, “Alterations in Prednisolone Disposition as a Result of Oral Contraceptive Use and Dose,” <i>Br J Clin Pharmacol</i>, 1984, 17:655-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6743464\">[PubMed 6743464]</a></p>\n<p>6. Slayter KL, Ludwig EA, Lew KH, et al, “Oral Contraceptive Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics,” <i>Clin Pharmacol Ther</i>, 1996, 59:312-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8653994\">[PubMed 8653994]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3398":"<p><b>Title</b> Atenolol / Ampicillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ampicillin may decrease the bioavailability of Atenolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of atenolol if ampicillin is initiated/dose increased, or increased effects if ampicillin antibiotic is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The bioavailability of atenolol was reduced by approximately 50% in 6 normal subjects when coadministered with ampicillin (1 g oral) in both a single dose and multiple dose setting (6 days).<sup>1</sup> The reduction was slightly greater in the 6-day arm of the study. The pharmacodynamics of atenolol were reduced. In another study, the bioavailability of atenolol following a 1 g dose of ampicillin was approximately 3 times greater than when the atenolol was administered following ampicillin 250 mg 4 times/day (51% and 18%, respectively).<sup>2</sup> The mechanism of this interaction is unknown. The effect of other penicillins on atenolol or other beta-blockers is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schafer-Korting M, Kirch W, Axthelm T, et al. Atenolol interaction with aspirin, allopurinol, and ampicillin. <i>Clin Pharmacol Ther</i>. 1983;33(3):283-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6825385\">[PubMed 6825385]</a></p>\n<p>2. McLean AJ, Tonkin A, McCarthy P, et al. Dose-dependence of atenolol-ampicillin interaction. <i>Br J Clin Pharmacol</i>. 1984;18(6):969-971. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6529538\">[PubMed 6529538]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}